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Abstract 
Adverse drug reactions (ADRs) are responsible for a high number of morbidities 
and mortalities worldwide and estimated to be the fourth most important cause of death in 
the US and Canada after heart diseases, cancer and stroke. ADRs are either type A 
(~80%) which are predictable, related to the drug pharmacology and dose-dependent or 
type B (~20%), which are unpredictable, unrelated to the drug pharmacology and have no 
clear dose-dependency. Drug hypersensitivity reactions (DHRs) represent the majority of 
type-B ADRs, which are rare but potentially fatal and unpredictable. The latter aspect 
makes DHRs very difficult to diagnose and necessitate the development of a reliable and 
safe in vitro diagnostic test to aid prediction and confirm diagnosis. The currently used 
tests are not well characterized and their predictive value is unknown. The aim of this 
work was to evaluate the clinical value of the currently used diagnostic tests for DHRs; to 
develop a simple, reliable and safe test; and to explore the pathophysiology of DHRs 
using different approaches for further understanding of the DHRs pathophysiology which 
will allow us to develop new means for prevention prediction and diagnosis. 
Methodology used involved performing systematic literature reviews, population 
survey on previously tested patients, patient recruitment and laboratory techniques that 
include preparation and testing of liver microsomes from human and animal origin, using 
hematopoietic cell lines and primary cultures of different blood cell types as a surrogate 
model to explore DHRs pathphysiology and test patient susceptibility for DHRs.  
Systematic review of available literature revealed that the currently used 
diagnostic tools for DHRs lack any characterization or standardization and much more 
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work is needed to further characterize and improve these tools. We developed a novel 
laboratory approach for diagnosis of DHRs that proved to be less cumbersome and 
potentially more reliable than other currently used tests. Using different biochemical and 
genetic methods, we introduced novel concepts that explain some aspects of the 
pathophysiology of DHRs. 
The main achievement in this research was the development of a novel diagnostic 
test for DHRs, the in vitro platelet toxicity assay (iPTA), which has a great potential as a 
clinical tool due to its simple procedure and good reproducibility. We hope that these 
features will allow its wider clinical use as oppose to other currently used tests. In 
addition, expanding our understanding of the molecular pathophysiology of DHRs using 
recent technical advances in genetic analysis and laboratory techniques will have a great 
impact on the management of these cases.        
Keywords 
Adverse drug reaction, drug hypersensitivity, in vitro diagnosis, in vitro platelet toxicity 
assay, the lymphocyte toxicity assay. 
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Preface 
This „integrated articles‟ thesis is based on 6 papers I have published over the last 
3 years, all focusing on examination of the predictive value of in vitro tests for drug 
hypersensitivity reactions (DHRs). These idiosyncratic reactions are often very severe 
and may result in serious morbidity and mortality. Hence, it is critical to create and 
validate laboratory methods that can identify vulnerable patient before serious reactions 
occur.  
After presentation of my hypotheses and objectives, I present two systematic 
critical reviews of the currently available in vivo and in vitro methods used for diagnosis 
and prediction of DHRs. This is followed by description and validation of a new 
laboratory method, the in vitro platelet toxicity assay (iPTA), developed by me during the 
tenure of my PhD. 
The thesis is concluded by an overall discussion of the state of the art of all 
aspects of in vitro testing for DHRs. 
Thank you for your participation and interest in my work. 
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Chapter 1: Objectives and hypotheses. 
1.1. Objectives: 
1) To systematically review the literature on patch testing for diagnosis of 
hypersensitivity reactions (DHRs). 
2) To systematically review the literature on in vitro testing for diagnosis of DHRs. 
3) To characterize the predictive value of the lymphocyte toxicity assay (LTA) for 
the diagnosis of DHRs. 
4) To develop and validate an in vitro platelet toxicity assay (iPTA) for drug 
hypersensitivity syndrome. 
5) To distinguish between different mechanisms of carbamazepine (CBZ)-induced 
hypersensitivity syndrome using novel tests and biological markers. 
1.2. Hypotheses: 
1) The available patch tests are not sufficiently standardized and their sensitivity and 
specificity are not adequately determined. 
2) The available in vitro tests for hypersensitivity syndrome are not standardized and 
reproducible to be used clinically. 
3) The predictive value of the LTA for aromatic anticonvulsants and sulfonamides- 
induced DHRs allows it is clinical use. 
4) The iPTA is more sensitive and predictive than the older LTA. 
5) In vitro testing using iPTA and LTA and the use of genetic markers such as the 
HLA allow identifying two separate mechanisms of CBZ-induced DHRs. 
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Chapter 2: Patch testing for the diagnosis of anticonvulsant hypersensitivity 
syndrome: a systematic review. 
This chapter has been published previously: 
Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for 
the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug 
Saf. 2009;32(5):391-408. 
 
 
 4 
 
 
2.1. Introduction 
Adverse drug reactions (ADRs) have been defined as undesirable effects associated 
with the therapeutic use of drugs.
[1]
 An ADR is defined by the WHO as noxious and 
unintended response to a drug that occurs at a dose normally used in man for prophylaxis, 
diagnosis or therapy.
[2]
  ADRs represent a major health problem world-wide with high 
rates of morbidity and mortality.
[3-6]
 Lazarou and colleagues
[4]
 have estimated in a meta-
analysis that ADRs were responsible for nearly 100 000 deaths in the US in 1994. Despite 
the fact that this study has been criticized,
[7]
 it does lend credence to the seriousness of 
this problem. Indeed, the authors of this study have estimated that ADRs are ranked 
between the fourth and sixth leading cause of death, after heart disease, cancer, stroke, 
pulmonary disease and accident, in the US and Canada. It has also been demonstrated 
that drug-related injuries occur in at least 7% of hospitalized patients,
[4]
 although accurate 
estimation of such cases is difficult due to under-reporting.
[8]
 In addition, ADRs also 
represent a serious economic burden on the health care system.
[9]
  
ADRs have been classified into the following two types: type-A reactions which are 
usually predictable, dose-dependent and related to the pharmacological action of the 
drug; and type-B reactions, which are unpredictable, have a delayed onset and cannot be 
explained by the pharmacological action of the drug.
[10]
 Type-B reactions are typically 
dose-independent; however, dose-dependence of these type of drug reactions can exist at 
higher dose ranges than conventional pharmacological dose-response relationships.
[11]
 
Type-B ADRs or idiosyncratic reactions (IRs) comprise various types of reactions such 
as immune-mediated (allergic, immunological reactions), which include drug 
hypersensitivity reactions or drug hypersensitivity syndrome (DHS), and non-immune-
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mediated (sometimes called metabolic idiosyncrasy).
[12]
 Gell and Coombs
[13]
 classified 
immune-mediated reactions into four types: type I reactions (immunoglobulin E-
mediated); type II reactions (through cytotoxic mechanisms); type III reactions (immune 
complex-mediated); and type IV reactions, which involve activation of T cells and are 
known as “delayed hypersensitivity”. Type IV reactions have recently been subdivided 
according to the heterogeneity of T-cell function into Types IVa, IVb, IVc and IVd.
[14, 15]
 
Although an elegant and mechanism-based classification system, many serious and 
probable immune-mediated ADRs do not fit into these established categories.
[16]
 DHS is 
thought to belong to type IV, T-cell mediated delayed reactions.
[17]
 
Drug hypersensitivity syndrome is a rare but potentially lethal host-dependent ADR 
that occurs in susceptible patients upon exposure to specific agents. It has been estimated 
that IRs, of which DHS represents a major component (around 10%), constitute from 3% 
to 25% of all ADRs.[18] Because of its unpredictable nature and potential severe 
morbidity and mortality, DHS is a major problem for patients, clinicians, drug regulators 
and the pharmaceutical industry and often deprives patients of effective therapy. 
The nomenclature of this type of drug hypersensitivity reaction has long been a topic 
of debate.[19, 20] Dilantin hypersensitivity syndrome, sulfone syndrome, dapsone 
hypersensitivity syndrome, allopurinol hypersensitivity syndrome, drug-induced delayed 
multiorgan hypersensitivity syndrome (DIDMOHS), anticonvulsant hypersensitivity 
syndrome (AHS), drug rash (reaction) with eosinophilia and systemic symptoms 
(DRESS) and drug-induced hypersensitivity syndrome (DIHS) have all been suggested as 
names and acronyms for this disorder.
[20, 21]
 Although no consensus has emerged thus far, 
the last three are the most widely used terms. However, for the purpose of this review, it 
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was felt that AHS is the most relevant term because only reactions related to aromatic 
anticonvulsant drugs (ACDs) were reviewed. 
The objective of this systematic review was to critically review all the relevant 
publications related to the use of the patch test in the diagnosis of AHS. We also aimed at 
discussing the technical aspects of this in  vivo test that contribute to its performance. 
2.1.1.  Anticonvulsant Hypersensitivity Syndrome (AHS) 
Aromatic ACDs such as phenytoin, carbamazepine and phenobarbitol as well as 
some newer agents, including lamotrigine, oxcarbazepine, felbamate  and zonisamide 
(figure 1), have been implicated in eliciting a whole repertoire of hypersensitivity 
reactions ranging from simple maculopapular skin eruptions to a severe life-threatening 
disorder. Upon exposure to an implicated drug, a constellation of symptoms develop 
including fever, skin eruption and internal organ dysfunction.
[22-33]
 Implicated drugs 
include aromatic anticonvulsants (carbamazepine, phenytoin, phenobarbital, lamotrigine), 
sulfonamide antibacterials, dapsone, minocycline, terbinafine, azathioprine and 
allopurinol.[34] Although AHS is typically defined by the triad of symptoms (i.e. fever, 
skin rash and internal organ involvement), it is quite difficult to associate a typical 
clinical picture to this syndrome as AHS can manifest as a wide range of clinical 
symptoms. Affected patients may develop fever, a skin eruption (from a mild skin rash to 
severe eruptions such as Stevens-Johnson syndrome and toxic epidermal necrolysis), and 
internal organ involvement (either asymptomatic or symptomatic).
[1, 28, 35]
 The 
multivisceral involvement of this illness may include blood dyscrasias (e.g. eosinophilia, 
thrombocytopenia), hepatitis, nephritis, myocarditis, thyroiditis, interstitial pneumonitis  
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Fig. 1. Chemical structure of aromatic anticonvulsant drugs. 
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and encephalitis. Other clinical features of AHS are facial oedema, tonsillitis, pharyngitis, 
mouth and lip ulcers, enlargement of liver and spleen, myopathy and disseminated 
intravascular coagulation.
[35-39]
 It has been estimated that the incidence of AHS lies 
between 1 in 1000 to 1 in 10 000 among patients chronically treated with phenytoin and 
carbamazepine.
[40]
 However, these incidences are believed to be inaccurate as a result of 
under-reporting.
[41]
 
The exact molecular mechanisms involved in AHS are not well understood. In 
fact, it is thought that multiple mechanisms are involved, sometimes simultaneously, to 
produce a single event.
[39, 42]
 Discussing detailed molecular mechanisms underlying AHS 
is beyond the scope of this review; nonetheless, some recent comprehensive reviews on 
this subject are available.
[39, 43, 44]
 In general, AHS is believed to be immune-mediated in 
all cases,
[17, 45]
 and the generation of reactive electrophilic drug metabolites that react 
selectively and non-enzymatically at nucleophilic sites on multiple proteins to form 
immunogenic drug metabolite-protein adducts is proposed to be the initial mechanistic 
step in the cascade of cell-based reactions that results in the clinical symptoms.
[33, 46-48]
 At 
least a few of the proteins that are covalently modified by metabolites of drugs causing 
AHS are likely to be involved in eliciting the immune response that characterizes these 
hypersensitivity reactions.
[39, 46, 49]
 
2.1.2. Diagnosis of AHS 
A validated, gold standard in vitro test for diagnosis or prediction of AHS is not yet 
available. In fact, the value of all currently used in vivo and in vitro tests is widely 
controversial and their sensitivities, specificities and variability are yet to be 
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determined.
[50-54] 
Currently, the diagnosis of AHS is based on clinical expertise that is 
comprised of: (i) a thorough clinical history, including detailed medication history; (ii) a 
comprehensive physical examination; and (iii) available laboratory data. Misdiagnosis of 
AHS is very common because the syndrome resembles other conditions such as 
infections, collagen vascular disorders and haematological/oncological conditions.
[24, 39]
 
An in vivo systemic rechallenge (drug provocation testing or controlled re-exposure) is 
considered to be the gold standard in AHS diagnosis,
[55]
 although ethically this is highly 
contentious, as a rechallenge with the implicated drug may result in severe morbidity or 
even death. Presently, there are at least three tests available for diagnosis of AHS, namely 
the patch test, the lymphocyte transformation test (LTT) and the lymphocyte toxicity 
assay (LTA).
[50, 55-58] 
The use of the patch test for the diagnosis of AHS is reviewed here. 
2.2.  Research Methodology 
 We performed the systematic literature search using the databases PubMed, 
EMBASE and MEDLINE from their commencement to the 4th week of August 2008 
(figure 2). 
2.2.1. Search strategies 
 The first search (Search strategy I) was carried out using key words 
“anticonvulsant” and “antiepileptic” in their singular, plural and truncated forms. These 
terms were also mapped to their medical subject headings (MeSH) terms. We also 
searched for individual aromatic ACDs including „carbamazepine‟, „phenytoin‟, 
„phenobarbital‟, „oxcarbazepine‟, „primidone‟, „lamotrigine‟, „felbamate‟ and 
„zonisamide‟ both as key words and as MeSH terms when available and the option 
„explode‟ was used. The obtained results were combined using „OR‟. 
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 In addition, a second search (search strategy II) was carried out using the key 
words „skin test‟, „patch test‟ and „epicutaneous test‟ in their singular, plural and 
truncated forms. These terms were also mapped to their MeSH terms when available and 
the option „explode‟ was used.  
 The results of the first and second searches were then combined using „AND‟. 
The search results were then limited to original articles that were published in English 
language and performed on human subjects. At this point, we retrieved 244 articles from 
PubMed, 163 articles from  MEDLINE and 184 articles from EMBASE. These 
publications were then manually reviewed and the following selection criteria were 
applied: (i) original articles; (ii) used patch testing for the purpose of diagnosis of 
suspected AHS as a result of one or more aromatic ACD(s); and (iii) contained sufficient 
technical data. 
 Applying our selection criteria, 54 articles from PubMed, 43 articles from 
MEDLINE and 42 from EMBASE were found to meet our selection criteria. The search 
results from the three databases were then combined and duplicates were removed. The 
final number of included articles from the three databases was 55. 
2.3. Patch Tests in the Diagnosis of AHS 
 Patch testing utilizes the concept that a localized, confined, immune-mediated 
reaction to the agent of concern can be reproduced by introducing the agent through the 
skin. Briefly, the patch test is performed by applying the drug to the tested (ground 
commercially available tablets, liquid forms or pure drug powder) on the skin (usually the 
upper back) using different devices that give standard surface area exporure. One widely 
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Fig. 2. Flow chart of literature search and retrieval process. 1, Search strategies 
„anticonvulsants‟ and „patch test‟ include all relevant medical subject headings and key 
words as described in the Research Methodology section; AHS = anticonvulsant 
hypersensitivity syndrome. 
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used device is the Finn chamber. The drug is diluted in suitable media (usually 
petrolatum, water or ethanol) and the media alone is used as control. The test is then read 
for appearance of local reaction after different time periods (20 minutes to 4 days).
[59]
 
This concept has been proven and extensively used for contact irritants and 
systemically administered drugs such as the β-lactam antibacterials.[60, 61] Presently, the 
positive predictive value (PPV) and the negative predicative value (NPV) of the patch 
test in the diagnosis of AHS remain to be determined and its real value is still 
unknown.
[50]
 The percentage of concordance between clinically suspected 
hypersensitivity reactions and positivity of patch testing varies considerably because of 
lack of test standardization.
[42, 45, 62]
   
2.4. Determinants Affecting Patch Test Results 
2.4.1. Epicutaneous Penetration 
 An important determinant of patch test success is the ability of the tested agent 
(drug) to cross the skin (epicutaneous penetration) and come into contact with the 
processing cells of the immune system (presumably dendritic cells).
[63]
 This property 
depends largely on the physicochemical characteristics of the drug to be tested, its 
concentration/formulation and the vehicle in which the drug is dispersed or solubilized. 
The physicochemical characteristics of the drug determine its polarity and lipid-
solubility, thus affecting the ability of the drug to cross the skin barrier and reach the 
target cells.
[64]
 In this regard, either the drug itself or its reactive metabolite can be used, 
although many reactive metabolites are not available commercially because of their 
instability, and purity of the reactive metabolites tested in this manner is an issue. In 
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addition, reactive metabolites may not be able to cross the epithelial barrier as they tend 
to be less lipophilic and, in some cases, the reactive metabolite is unknown. 
Unfortunately, it is not yet possible to comment on the benefit of using metabolites of 
ACDs in patch testing because of the paucity of literature on this subject.
[53, 62]
 There are 
also cases where opposing results have been obtained when patch testing a drug and its 
main metabolite in the same patient.
[62, 65]
 Surveying the literature, it seems that the 
ACDs that  are most commonly involved in eliciting AHS  are carbamazepine and, to 
some degree phenytoin. This may be because of frequency of use of carbamazepine and 
phenytoin as opposed to prevalence of AHS, therefore, it is not surprising to find many 
more investigators interested in studying the toxicity of these drugs compared with other 
ACDs. Another  possible reason for choosing to work with carbamazepine is because it is 
easier to work with in regard to the frequency of positive results in highly imputable 
cases. 
 Once absorbed, carbamazepine is initially metabolized in the liver (or skin) via 
cytochrome P450 (CYP) 3A4 and CYP2C8, into at least 33 different metabolites.
[66-69]
 
One of the main metabolites that is also known to have pharmacological activity is 
carbamazepine 10,11 epoxide, which  is stable and available commercially for research 
purposes. Lee et al.
[62]
 patch tested both carbamazepine and carbamazepine 10, 11 
epoxide on 13 patients who had exhibited a skin reaction to carbamazepine manifested as 
a maculopapular cutaneous eruption. Seven of the 13 patients gave positive patch tests 
with the parent drug but negative results with the metabolite; two reacted only to the 
metabolite and 1 patient tested positive to both agents. In the same study, all 39 control 
subjects who were taking antiepileptic drugs including carbamazepine gave negative 
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patch test results to both carbamazepine and carbamazepine 10,11 epoxide. Although the 
PPV of the patch test for carbamazepine in this study was good (61.5%), the low 
percentage of positive tests when using carbamazepine 10,11 epoxide (23.0%) is difficult 
to explain. The authors interpreted these results to be due to either the low concentration 
of carbamazepine 10,11 epoxide used or to efficient metabolism of carbamazepine 10,11 
epoxide, for example by epoxide hydrolase, in some of the patients. The latter 
explanation is more likely. 
 The use of a reactive metabolite in patch testing has always been hindered by lack 
of knowledge of the role of each metabolite of a drug in eliciting hypersensitivity 
reactions and response to the exact testing procedure as well as lack of availability of 
most of the suspected metabolites due to their chemical instability. Duhra and Foulds
[66]
 
patch tested carbamazepine and oxcarbazepine as well as some of their metabolites (but 
not carbamazepine 10,11 epoxide) in a patient with suspected carbamazepine 
hypersensitivity. Only carbamazepine gave positive patch test results and they suggested 
that the double-bond between positions 10 and 11 of the azepine ring (figure 1) is critical 
for skin reactivity. No other study is available in the published literature using patch 
testing with metabolites of ACDs. 
2.4.2. Type of Drug Tested 
 It has been shown that the predictive value of a patch test depends largely on the 
type of drug implicated in the ADR.[59]  Galindo et al.
[70]
 have investigated 23 different 
types of ADR, including generalized rash, fever, arthralgia, lymphadenopathy, palpable 
purpura, facial erythema, angio-oedema and erythema multiforme, developed to ACDs  
in 15 patients using patch testing. They found the patch test to be most useful for ADRs 
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involving carbamazepine (PPV 75%) and phenytoin (PPV 60%), whereas the rate for a 
positive test was very low (25%) with phenobarbital and lamotrigine. The good PPV 
observed with carbamazepine does not seem to be affected by the vehicle used, i.e. 
whether it is liquid (water or ethanol) or semisolid (petrolatum).
[30, 71]
 One explanation for 
the good PPV of patch testing with carbamazepine could be its high lipophilicity, which 
may facilitate its percutaneous penetration and intracellular movement during patch 
testing. Indeed, carbamazepine has very good lipophilic properties and a log Koct value of 
2.7, which is near the optimum value of 2.5 for transdermal permeation, although other 
parameters can be enhanced through some modifications to the chemical structure of the 
compound.
[72]
  
2.4.3. Concentration of Tested Drug 
 The ideal drug concentration in patch testing of anticonvulsants is critical in 
obtaining positive results in affected patients without inducing non-specific local 
irritation, which may be falsely interpreted as positive results.
[60]
 The concentration 
selected should give negative results in control subjects.
[73]
 Because the exposed surface 
area of the skin is standard (e.g. using Finn chambers) the amount of drug used is always 
expressed as concentration (weight by volume). In published data, the drug concentration 
used with ACDs ranged from 0.0001% to 100% pure substance, but the most commonly 
used concentrations were between 1% and 10%. However, 0.1% has been the lowest 
reported concentration at which a positive patch test to carbamazepine was observed.
[74-
76]
 
 It has been recommended to use pure drug, whenever available, in order to avoid 
false-positive results due to hidden additives in the drug formulations
[77]
,degradation 
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products or impurities. In all cases, certain guidelines for the preparation of commercially 
available drug formulae for patch testing have been suggested.
[59, 73]
  
2.4.4. Vehicle 
 Petrolatum has been a preferred medium for patch testing of skin sensitizers 
because it gives good occlusion and prevents drug degradation as a result of 
hydrolysis.[78] Its use has yielded satisfactory results with patch testing of ACDs,
[27, 30, 62, 
64, 74-76, 79-86]
 although, other liquid solvents, such as water,
[87]
 saline,
[79]
 ethanol,
[88]
 
methanol,
[89]
 acetone
[90]
 and propylene glycol,
[91]
 have also been used. Nonetheless, it 
appears that using different vehicles does not alter the results,
[71]
 although some liquid 
vehicles evaporate during the test, possibly affecting the concentration at which the drug 
is introduced. 
 In addition, applying control patches of the vehicle at the same time as the drug is 
critical because some patients may be sensitive to the vehicle itself especially if it is not 
of high purity.
[92]
 The state of the drug in aqueous vehicle or in a semisolid medium, such 
as petrolatum, are different since the compound may dissolve in the liquid vehicle but be 
dispersed as undissolved crystals in the semisolid medium. Thus, we might expect to 
have better delivery of the drug using the liquid vehicle rather than petrolatum. In fact, 
using in vitro mounted human skin and chromate preparations as a model, Gammelgaard 
et al.
[93]
 demonstrated a better skin permeation of the chemical (potassium dichromate) 
with aqueous vehicle. It is also interesting to note that paracetamol (acetaminophen) gave 
a positive patch test when using an aqueous vehicle and negative patch test when 
petrolatum was used as the vehicle.
[27] 
 
2.4.5.  Timing 
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 Another factor that seems to be critical to the final result of patch testing is the 
timing of the test in regard to the beginning of the hypersensitivity reaction. Some 
authors
[94]
 have recommended performing the patch test within 6 months following the 
reaction to avoid false-negative results because it is not known how long drug reactivity 
lasts. However, others have recorded positive patch tests 6 months to 2 years after the 
reaction.
[76, 80, 84, 87, 95, 96]
 In fact, positive patch test results have been obtained in patients 
tested 12 years after the adverse reaction to drugs such as sulfamethoxazole.
[97]
 This may 
not be surprising as drug-specific T cells can be detected for decades following an 
adverse reaction.
[45]
 It is not known if this phenomenon of long-lasting drug reactivity is 
drug-dependent, although the frequency of drug-specific T cells is apparently drug-
dependent.
[97]
 
 On the other hand, Jones and coworkers
[80]
 have reported false-negative patch test 
results to carbamazepine when the test was performed during or right after the 
hypersensitivity episode. In contrast, others
[30]
 have warned about false-positive patch test 
results if the test is performed during the increased reactivity period of the 
hypersensitivity reaction and recommend waiting for at least 2 months after the 
subsidence of the reaction before performing the test. However, positive patch test results 
have been obtained when the test was performed during or right after recovery from the 
reaction.
[27, 71, 79, 85, 90, 98-100]
 
 In reviewing different studies, it seems obvious that performing patch tests during 
the acute phase of the reaction appears to yield low rates of positive results,
[88, 100-102]
 and 
the optimal timing for the test in this regard appears to be between 2 and 6 months after 
the reaction. No mechanistic explanation is available as to why the reaction is not 
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detectable early on; however, some have speculated that transient immune depression 
during the reaction produces this refractory period.
[102]
 Others propose that transient 
selective recruitment of antigen-specific lymphocytes into target organs may lead to the 
low number of such cells in the peripheral blood, and thus low reactivity. 
[84]
 However, in 
the case reported by Okuyama et al.,
[102]
 other factors may have contributed to the 
negative results of the patch tests for carbamazepine hypersensitivity during and 
immediately after the reaction, including topical and oral co-administration of steroids 
during the illness. This observation is supported by the appearance of slightly positive 
LTTs during the early stages of the reaction. 
2.4.6. Clinical Picture 
 The clinical picture of the AHS seems to correlate with patch test results, in that 
patients with certain types of clinical manifestations seem to react differently to the test. 
This is because the clinical manifestations reflect the underlying and integrated 
immunological mechanisms of the „reactions‟, which probably differ in one or more 
aspects from patient to patient and from one drug to another in individuals.
[101, 103]
 Some 
of these underlying reactions are unlikely to be recognized by patch testing, or may not 
involve the immunological mechanisms that the patch test was designed to detect. For 
instance, when the patch test was used on patients who developed different types of 
cutaneous ADRs, such as exanthemas, fixed drug eruptions or urticaria, more positive 
results were observed with exanthema patients than in patients with other types of 
cutaneous ADRs.[50]  
 Similarly, Alanko
[71]
 studied 18 patients with different forms of cutaneous 
reactions to carbamazepine. Of these, 15 were confirmed by oral rechallenge. Patients 
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with maculopapular exanthematous eruptions, exfoliative erythrodermas or erythema 
multiforme were found to give positive patch test results in about 70% of those tested, 
whereas those with other types of skin reactions including fixed drug eruptions, urticaria 
and other types of exanthema all had negative patch test results. However, Alanko et 
al.
[104]
 could demonstrate positive patch test results in patients with fixed drug eruption 
only if the test were performed on the site of old lesion and not on unaffected skin. 
Similarly, Galindo and coworkers
[70]
 have also suggested a correlation between the 
histological features of the hypersensitivity reaction and the predictability of testing such 
as patch tests. Puig et al.
[75]
 reported that the clinical type of ADR plays a critical role in 
the sensitivity of the patch test, which appears to be maximal for maculopapular or 
morbilliform reactions. 
 Of particular importance, delayed hypersensitivity reactions may take more than 
one cutaneous form, even in the same patient.
[45, 105]
 Cutaneous manifestations of 
reactions to ACDs come in many different forms,
[28]
 some of which could be of pseudo-
allergic nature,
[106, 107]
 i.e. they may not be mediated by the usual immune mechanisms. 
Those reactions, although they mimic true allergic reactions, are unlikely to be detectable 
by the patch test.
[52] 
This may explain the low rate of positive patch test results on AHS 
patients reported by some investigators.
[50, 53, 81, 86, 100]
  
2.4.7. Other Factors 
 Other factors that may affect the outcome of the patch test in general are age, sex 
and ethnic origin of the patient. Many parameters of skin function, such as thickness, pH, 
blood flow and content of lipid, water and protein, are known to change during 
ageing.
[108-111]
 These changes can affect the ability of the applied drug to penetrate the 
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skin and elicit its effects. With contact allergy, contradictory literature reports have 
appeared regarding the effect of age, sex and ethnic origin on results of the patch test.
[109, 
112, 113]
 However, these factors have not been evaluated directly in patch testing of ACDs, 
and further comprehensive work is essential if the contributions of these factors to the 
variability in patch test results are to be completely understood (table I). 
2.5. Discussion 
 Our systematic review reveals that there is a deficiency in large-scale studies 
determining the usefulness of patch testing in the diagnosis of AHS. Lammintausta and 
Kortekangas-Savolainen
[50]
 performed a retrospective study analysing the result of skin 
tests including patch testing performed on 947 patients with suspected cutaneous ADRs 
during a 13-year period, of whom 56 patients had been exposed to ACDs. Tested patients 
had developed a wide range of cutaneous symptoms including exanthema, urticaria, 
angio-oedema, fixed drug eruption, vasculitis, purpura and erythema multiforme. 
Unfortunately, the percentage of positive tests among these patients was lower than 20% 
and no oral rechallenge was performed to validate the predictive value of the patch test in 
such cases. 
 In another study to investigate the suitability of the patch test or the LTT to detect 
carbamazepine allergy, Troost and colleagues
[88]
 tested a number of patients using both 
techniques. Correlation between positive results of both tests was rather low (r = 0.39, p 
= 0.0022). Among a total of 59 patients displaying adverse effects to carbamazepine, 23 
had positive LTTs and only 8 of the 23 LTT-positive patients had a positive patch test 
(35%). 
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 Among the published studies, the PPV of the patch testing seems to depend on the 
type of antiepileptic drug under investigation, with the highest values obtained with 
carbamazepine and the lowest with phenobarbital. These values range from 20% to 80%; 
however, it is difficult to draw a firm conclusion because in most of the cases it is only 
the medical history of the patients, which provides any evidence of the drug involved. 
Oral rechallenge would help confirm the identity of the suspect drug, but because of the 
possible severity of the reaction, a systemic rechallenge is rarely performed.  
The PPV of the patch test in the diagnosis of AHS appears to be higher than its NPV. 
This trend is expected because there are two types of determinants in achieving a positive 
patch test: (i) the technical and toxicokinetic characteristics of the agent prior to its 
introduction to the immune cells; and (ii) the readiness of the immune system to 
recognize this agent and elicit its distinct reaction. Both of these types of factors appear to 
contribute to the success of the drug in eliciting a positive patch test. In fact, some 
investigators believe it is quite “astonishing” that the patch test can give a positive 
reaction at all.[52] This doubt is especially relevant for drugs in which the mechanism of 
hypersensitivity is believed to involve long and complex pathways. Positive patch test 
results in AHS can be indicative of patient sensitivity to the drug (high PPV) but negative 
ones are not conclusive (low NPV) as false-negative results have been described.
[136]
  
The patch test is capable only of detecting a rather strong inflammatory reaction and this 
capability depends on how many inflammatory components are involved in the 
hypersensitivity reaction.
[52]
 Therefore, weak or intermediate immune responses are 
unlikely to be detected by patch testing. Recent advances in genetic research have 
allowed the discovery of associations between genetic polymorphisms in certain genes 
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Table I. Summary of data: use of patch testing to investigate anticonvulsant hypersensitivity syndrome 
Type of study 
No. of 
pts 
No. of 
controls 
Druga 
Conc. 
[w/v] 
(% unless 
otherwise 
indicated)  
Vehicle Timeb 
Frequency 
of positive 
result (%)  
Reference 
Case report 
 1 10 Phenytoin 1, 5 Sal 6 mo 1/1  
  1 10 Carbamazepine 0.1–20 Sal 6 mo 0/1  
  1 10 
Phenobarbital 
(phenobarbitone) 10–20 Sal 6 mo 0/1 [114] 
Case series  1  0 Carbamazepine 0.1–10 NA 4 wK  1/1 [115] 
Case series  1  0 Phenytoin 1 Wat DUR 1/1  
  4  0 Carbamazepine 5 Petr DUR 3/4 (75) [27] 
Case series  8 34 Carbamazepine 5–20 Petr 1–120 mo 6/8 (75)  
  1 34 Phenobarbital 5–20 Petr 1–120 mo 1/1  
  1 34 Oxcarbazepine 5–20% Petr 1–120 mo 1/1  
  1 34 Valproic acid 15–60 Petr 1–120 mo 1/1 [116] 
Case report  1  0 Phenytoin 1, 10 Petr/wat 3 mo  1/1
c
  
  1  0 Carbamazepine 1, 10 Petr/wat 3 mo  1/1
c
 [30] 
Case report  1  0 Carbamazepine NA NA NA 1/1 [117] 
Retr. cohort  37  5 Carbamazepine 
1–30 
g/mL 
Petr/sal/eth 2 mo–20 y 7/37 (18.9)  
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Type of study 
No. of 
pts 
No. of 
controls 
Druga 
Conc. 
[w/v] 
(% unless 
otherwise 
indicated)  
Vehicle Timeb 
Frequency 
of positive 
result (%)  
Reference 
  6  5 Phenytoin 
1–30 
g/mL 
Petr/sal/ eth 2 mo–20 y 2/6 (33.3)  
  8  5 Oxcarbazepine 
1–30 
g/mL 
Petr/sal/ eth 2 mo–20 y 1/8 (12.5)  
  5  5 Lamotrigine  
1–30 
g/mL 
Petr/sal/ eth 2 mo–20 y 0/5 (0%) [50] 
Case report  1  3 Phenytoin 50 mg/mL NA 2 mo 1/1 [118] 
Case report  1 10 Carbamazepine 10 Petr NA 1/1 [83] 
Case series  1 10 Phenytoin 12.5 PBS NA 1/1  
  1 10 Carbamazepine 20 PBS NA 1/1  
  1 10 Oxcarbazepine 12.5 PBS NA 1/1 [119] 
Case series 10 40 Phenytoin 10 Petr/eth NA 3/10 (30) [81] 
Case report  1  3 Valproic acid Pure Pure 3 mo  1/1 [120] 
Case report 13 39 Carbamazepine 10 Petr NA 7/13 (53.8)  
 13 39 
Carbamazepine 
10, 11 epoxide 
1 g/mL Eth NA 3/13 (23) [62] 
Case series  8 20 Carbamazepine 5 Wat >2 mo 5/8 (62.5)  
  5 20 Phenytoin 5 Petr >2 mo 3/5 (60)  
 26 
 
 
Type of study 
No. of 
pts 
No. of 
controls 
Druga 
Conc. 
[w/v] 
(% unless 
otherwise 
indicated)  
Vehicle Timeb 
Frequency 
of positive 
result (%)  
Reference 
  4 20 Phenobarbital 5 Petr >2 mo 1/4 (25) [70] 
Case report  1  5 Lamotrigine 10 Petr DUR 1/1 [98] 
Case report  1  0 Carbamazepine NA NA 1 wk 0/1 [121] 
Cohort study  1 20 Carbamazepine 400 g/mL PBS 6–8 wk 0/1 [122] 
Case report  1  0 Carbamazepine 0.1, 1, 2 Petr 1–2 wk 1/1 [123] 
Case report  1  0 Lamotrigine 50 Petr 2 d 1/1 [124] 
Case report  1  0 Carbamazepine 5 Petr/sal Aft. Rec.  1/1 [87] 
Case report  1  0 Valproic acid 20 Wat 9 mo 1/1 [125] 
Case report  1 15 Carbamazepine 1, 5 Petr 5 mo 1/1 [121] 
Case series  2  0 Carbamazepine 1, 5 Petr NA 1/2 [125] 
Case report  1 20 Phenytoin 1–20 Petr/wat 2 mo 1/1 [126] 
Case series 20  0 
Carbamazepine, 
phenytoin, 
phenobarbital 
10 NA NA 12/20 (60) [34] 
Case series  4  5 Carbamazepine 1, 10 Petr >1 mo 4/4 (100) [86] 
Case report  1  0 Carbamazepine 0.1–10 Petr/wat 3 mo 0/1 [127] 
Case series 11 20 
Carbamazepine, 
Phenobarbital 
1 Petr 3–8 wk 5/11(45.5) [86] 
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Type of study 
No. of 
pts 
No. of 
controls 
Druga 
Conc. 
[w/v] 
(% unless 
otherwise 
indicated)  
Vehicle Timeb 
Frequency 
of positive 
result (%)  
Reference 
Case report  1  0 
Carbamazepine, 
phenytoin, 
oxcarbazepine 
10 Eth 2 mo 1/1 [99] 
Case series 61 11 Carbamazepine 10 Eth DUR 12/61 (20)  
 59 11 Oxcarbazepine 10 Eth DUR 8/59 (14) [88] 
Case series  7 40 Carbamazepine 1, 5, 10 Petr >1 mo 6/7 (85.7) [75] 
Case report  1 10 Phenytoin 1 Petr NA 1/1  
  1 10 Carbamazepine 1 Petr NA 1/1  
  1 10 Phenobarbital 5 Petr NA 0/1 [128] 
Case report  1  5 Carbamazepine 2 Petr Right after 0/1  
  1  5 Carbamazepine 1 Petr 3 mo 1/1 [102] 
Case series  4 12 Carbamazepine 0.1–100 Petr/ace 
0, 1.5,4 and 6 
y 
4/4 (100) [129] 
Case report  1  0 Carbamazepine 0.1–10 Per 4 mo 0/1
d
 [130] 
Case report  1  5 Carbamazepine 1 and 5 Meth NA 1/1 [89] 
Case series  5 20 Carbamazepine 1 Petr 3 mo–5 y 4/5 (80%) [80] 
Case series  3  0 Carbamazepine 10 
Petr/eth/DM
SO  
NA 3/3 (100) [131] 
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Type of study 
No. of 
pts 
No. of 
controls 
Druga 
Conc. 
[w/v] 
(% unless 
otherwise 
indicated)  
Vehicle Timeb 
Frequency 
of positive 
result (%)  
Reference 
Case report  1  9 Carbamazepine 10, 20,40 YSP 3 y 1/1 [96] 
Case series 18 20 Carbamazepine 3, 10 Petr/wat/eth DUR 9/18 (50) [71] 
Case report  1  0 Carbamazepine 100 Pure Right after 0/1 [66] 
Case report  1 20 Carbamazepine 0.1, 1 Petr 4 wk 1/1  
  1  0 Carbamazepine 10 Petr 4 wk 0/1 [132] 
Case report  1  0 Carbamazepine 0.001–5 Petr NA 1/1
c
 [74] 
Case series 25 10 
Carbamazepine, 
Oxcarbazepine 
NA NA NA 6/25 (24) [53] 
Case series  6  0 Carbamazepine 0.3–20 Petr/sal NA 4/6 (67)  
  2  0 Phenytoin 0.3–20 Petr/sal NA 1/2 (50)  
 10  0 Phenobarbital 0.3–20 Petr/sal NA 4/10 (40)  
  5  0 Valproic acid 0.3–20 Petr/sal NA 4/5 (80) [64] 
Case report  1  0 Carbamazepine 1, 10, 100 Ace/petr DUR 1/1 [90] 
Case report  1  0 Carbamazepine Cr.Tab Petr/wat DUR 1/1
c
 [85] 
Case report  1  0 Carbamazepine 0.0001–0.1 Petr 6 mo 1/1
c
 [76] 
Case series 10 80 Carbamazepine 1, 5, 10 Petr NA 3/10 (30) [133] 
Case report  1  0 Carbamazepine 1–10 Petr DUR 0/1 [100] 
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Type of study 
No. of 
pts 
No. of 
controls 
Druga 
Conc. 
[w/v] 
(% unless 
otherwise 
indicated)  
Vehicle Timeb 
Frequency 
of positive 
result (%)  
Reference 
Case series  3  0 Carbamazepine 1–10 Petr 4–7 mo 3/3 (100) [84] 
Case report  1  0 Carbamazepine Pure, 1 Petr/ace 3 mo 1/1 [134] 
Case report  1  0 Phenobarbital 20 Pr. gly Right after 1/1 [91] 
Case series  7 18 Carbamazepine 10, 20, 40 Petr 14 wk–7 y 6/7 (85.7) [95] 
Case report  1  4 Phenytoin 1, 5, 10 NA 5 mo 0/1  
  1  4 Carbamazepine 1, 5 NA 5 mo 1/1 [135] 
* = concentration in μg/ml. 
** = time elapsed between the reaction and the test. 
*** = Frequency of positive results (Percentage). 
§: positivity depends on concentration and/or vehicle used. 
¥: The suspected drug causing the reaction as suggested by at least the medical history of the patient(s). 
¶: Pt  with 10% in petr. was slightly positive at 3 days. 
Abbreviations: AC = anticonvulsant, Ace = acetone, AHS = anticonvulsant hypersensitivity syndrome, CBZ = Carbemezepine, CBZ-E 
= carbamazepine epoxde, Cr.Tab = crushed tablet, CT = number of control subjects, DPH = Phenytoin, DRG = drug, DUR = during, 
Eth = ethanol, LMT = Lamotrigine, M = month, Meth = methanol, Petr = petrolatum, PHB = Phenobarbital, Pr. gly = propylene glycol, 
PT = number of patients, Retr. = retrospective, Sal = saline, VA = valproic acid, Wat = water, Wk = week, Y = year, YSP = yellow soft 
paraffin. 
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(e.g. HLA-B and heat shock protein 70) and the risk of specific types of drug 
hypersensitivity reactions.
[137-143]
 However, no genetic marker has yet been identified that 
has sufficient predictive value to be used as a screening tool for AHS predisposition in 
the general population.
[138]
 A recent alert has been issued by the US FDA recommending 
screening all patients with Asian ethnicity for the HLA-B*1502 allele before prescribing 
carbamazepine because of the proven genetic association between this allele and a high 
risk of developing severe forms of hypersensitivity reactions (SJS/TEN).
[144] 
However, 
the Asian population consists of multiple ethnic groups that vary considerably in terms of 
genetic composition, including the frequency of the HLA-B*1502 allele. Furthermore, no 
link was found between this type of mutation and other non-bullous forms of 
carbamazepine-induced hypersensitivity reactions, making genetic screening useless in 
predicting patient susceptibility to these reactions.
[145]
 However, it is of interest that 
different polymorphic alleles were found to associate with specific forms of 
hypersensitivity reaction (maculopapular eruption, multiple organ syndrome, SJS, TEN), 
implying varying pathological mechanisms for each reaction. This may partially explain 
differences in patch test performance in patients developing different clinical 
manifestations of AHS. 
2.5. Conclusion 
 Patch testing is one of the tools that can be used to diagnose or predict AHS. It is 
apparent that patch testing can detect only a small portion of the immunological reactions 
that underlie AHS, therefore, other diagnostic methods, such as systemic rechallenge, 
LTA and/or LTT, should be utilized to make testing more reliable. However, the benefit 
of testing appears to be maximal with certain drugs (i.e. carbamazepine and phenytoin) 
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and for specific clinical manifestations (strong reactions). It should be performed 2–6 
months after recovery from the date of the ADR for best results, with adequate vehicle 
control. In addition, the test procedure must be standardized in order to evaluate its 
performance in the diagnosis of drug-induced hypersensitivity reactions. 
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3.1. Introduction 
Anticonvulsant hypersensitivity syndrome (AHS), also known as drug 
hypersensitivity syndrome (DHS) or drug rash with eosinophilia and systemic symptoms 
(DRESS), is a type B “Bizarre” adverse drug reaction (ADR) that develops in susceptible 
patient following exposure to certain drugs including aromatic anticonvulsants( figure 
1).
[1, 2]
 Although lacking a defined clinical picture, AHS is typically associated with 
development of skin rash, fever and internal organ dysfunction that may include blood 
discrasias, hepatitis, nephritis, myocarditis, thyroditis and interstitial pneumonitis and 
encephalitis.
[3]
 The pathophysiological mechanisms underlying AHS are not well 
understood; however it is believed to be immune mediated in general and involve 
generation of nucleophilic reactive metabolites that react covalently with macromolecules 
to form immunogenic adducts able to activate the immune system. 
[4, 5]
 The accurate 
incidence of AHS is unknown due to underreporting but it has been estimated to be from 
1 in 1000 to 1 in 10,000 in patient newly exposed to aromatic anticonvulsants. 
[6]
 While 
the disorder is rare,it is potentially fatal and represents a clinical dilemma to treating 
doctors. Diagnosis of AHS is challenging as a reliable and safe diagnostic test is not 
available to confirm causality or identify the culprit drug. A number of in vivo and invitro 
tests have been devised and used to aid the diagnosis of AHS.
[7, 8]
 These include skin tests 
(patch test, prick test, intradermal test), the lymphocyte transformation test (LTT) and the 
lymphocyte toxicity assay (LTA).
[9]
 The use of patch test in the diagnosis of AHS has 
been reviewed recently.[10] This systematic review is an attempt to evaluate the utility of 
in vitro tests used for the purpose of diagnosis of the T-cell-mediated type IV delayed 
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AHS reactions. Other tests used for other types of allergic reactions (e.g. IgE 
measurement, radioallergosorbent test, basophil activation test) are not reviewed here.  
In vitro diagnostic tests have the advantage over in vivo tests (patch test and 
rechallenge) of bearing no potential harm to patients. A number of in vitro diagnostic 
tests have been used to aid the diagnosis of delayed-type drug hypersensitivity reactions
[7, 
8, 11-13]
; however, their true value is yet to be defined. Among these tests are those that 
utilize peripheral blood monocytes (PBMCs) as target cells, including the LTT and the 
LTA. Unfortunately, these techniques require expensive equipment and sophisticated 
laboratories as well as specialized experience with biochemical and molecular methods 
so only a few centres are sufficiently equipped to perform them. Hence, these methods, 
although successfully employed as research tools, have not been successfully translated 
to diagnostic tests.
[14, 15]
 The specific aims of the current systematic review are 4-folds: (i) 
to evaluate the use of LTT and LTA in the diagnosis of AHS; (ii) to describe the 
advantages and limitations of these tests; (iii) to discuss different technical aspects of 
both tests with the scope of possible improvement; and (iv) to identify potential future 
work to increase the diagnostic value of these tests. The overall objective of this review is 
to identify gaps that must be closed to allow these tests to become validated, mainstream 
diagnostic tools. 
Leukocytes are present in peripheral blood at densities of 5-7 X 103 cells/mm3; 20 
to 50% of these cells are lymphocytes whereas 2 to 10% are monocytes. Lymphocytes 
are favoured as a model for investigation of immune-mediated diseases because of their 
unique characteristics, which include that (i) they are easily obtained at adequate density; 
(ii) they play a key role in the immune system by orchestrating different elements of the 
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Fig. 1. Chemical structures of aromatic anticonvulsant drugs. 
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immune response and thus representing the state of the immune system in the specific 
patient; (iii) they are metabolically active and expressing most of the enzymes that are 
required for drug detoxication; and (4) individual genetically-based defects in the 
expression or activity of these detoxication enzymes are phenotypically expressed in 
lymphocytes.
[1]
 
3.1.1. Isolation of peripheral blood mononuclear cells (PBMCs) 
Several methods have been used to isolate lymphocytes from heparinised whole 
blood including the gelatine method, passage through glass wool or beads as well as 
magnetic separation after cellular ingestion of carbonyl iron 
[16]
, However, the most 
successful and currently most used method is that developed by Böyem
[17]
. This method 
involves centrifugation of diluted blood samples through a gradient of Ficoll
®
, a synthetic 
high molecular weight polymer of sucrose that is highly branched and has low intrinsic 
viscosity.  This method permits recovery of 60 ± 20% of lymphocytes from original 
blood samples with cell viability greater than 90%. This technique allowed the use of 
isolated peripheral blood monocytes (PMBCs) in tests such as the LTT and LTA. 
3.1.2. The lymphocyte transformation test (LTT) 
The in vitro lymphocyte transformation phenomenon was first described during 
the late 1950s. In short, human peripheral leukocytes differentiate in short-term primary 
cultures, forming plasts. This effect was later attributed to the presence of a constituent, 
phytohemoagglutinin (PHA), of plant extract from red kidney beans (Phaseolus 
vulgaris), used to isolate blood peripheral leukocytes.
[18]
 PHA causes erythrocytes to 
aggregate and sediment allowing leukocytes to separate from whole blood 
preparations.
[19, 20]
 In a later report, Nowell
[21]
 demonstrated that PHA also initiates 
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mitotic activity (transformation) in cultured human leukocytes. To confirm the 
assumption that the effect of PHA on isolated peripheral blood leukocytes (PBL) has an 
immunological basis, Pearmain et al.
[22]
 exposed PBLs isolated from both tuberculin-
sensitive and non-sensitive patients to tuberculin in vitro. Only PBLs from tuberculin-
sensitive patients showed mitotic activity whereas cells from patients not previously 
exposed to the antigen showed no mitosis.  
One of the first reports of using this test for diagnosis of drug allergy was by 
Holland and Mauer who evaluated the effect of diphenylhydantoin (phenytoin; DPH) on 
cultured lymphocytes isolated from patients sensitive to the drug and non-sensitive 
(control) subjects. In these experiments, PHA, used as a positive control showed non-
specific stimulation of all cells sampled whereas DPH stimulated only the cells from 
DPH-sensitive patients.
[23]
 With peripheral lymphocytes isolated from a sulphadiazine-
sensitive patient, this effect was found to be concentration-dependent.
[24]
 In 1966, 
Vischer
[25]
 replaced the lengthy visual counting of mitotic figures from fixed slides with a 
faster and less subjective method by measuring radiolabelled thymidine incorporation 
into cellular DNA as a reflection of the rate of cell division. During the late 1960s and 
early 1970s a great deal of work was done by Schellekens and colleagues to optimize the 
in vitro lymphocyte transformation technique.
[26-30]
   
The terms Lymphocyte Transformation Test (LTT), Lymphocyte Stimulation Test 
(LST) and Lymphocyte Proliferation Test (LPT) are interchangeably used to describe this 
technique. The procedure includes incubation of PMBCs isolated from drug-
hypersensitive patients with the incriminated agent at non-toxic concentrations and 
observation of any increase in the rate of cell proliferation measured by [
3
H]thymidine 
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incorporation (figure 2). The increase in cell proliferation is expressed as a ratio between 
proliferation of cells incubated with and without the drug (control). This ratio is defined 
as the stimulation index (SI) and it is calculated as follows: 
 
Value of [
3
H]thymidine uptake, count per minute (cpm), in the presence of the drug  
Value of [
3
H]thymidine uptake (cpm) in the absence of the drug (vehicle 
alone) 
SI  = 
 
Cell cultures from drug-exposed and unexposed non-sensitive individuals are also used to 
confirm the specificity of a potential drug effect. The final result of the test depends on 
several factors such as the value of background cell proliferation and the type of the drug, 
however, an SI of > 3 is always considered indicative of a positive reaction.
[31]
 Other 
endpoints for measurement of T-cell activation such as elevation of released cytokines 
(using an enzyme-linked immunoabsorbent assay, ELISA) have been proposed and could 
be a more sensitive method for detection of T-cell activation than measurement of the 
rate of cell proliferation.
[31, 32]
 A recent technique based on staining of intracellular 
proteins with carboxyfluorescein succinimidyl ester (CFSE) has been used successfully to 
measure T-cell proliferation in vitro.
[33, 34]
 This fluorescent dye is used to non-specifically 
label intracellular proteins. In cell proliferation, the intensity of the fluorescent signal is 
progressively decreased as the stained proteins are divided during mitosis. An increase in 
number of low fluorescent cells indicates cell proliferation that can be measured by flow 
cytometry.
[35, 36]
  
The LTT has been used by some investigators for diagnosis of potential drug 
allergy cases for more than 20 years.
[37]
 However, its value in diagnosis and prediction of 
AHS remains controversial. 
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3.1.3. The lymphocyte toxicity assay (LTA)  
Introduced by Spielberg and colleagues[1, 38-41] in the 1980s, the LTA is an in 
vitro test which utilizes isolated PBMCs to investigate the pathogenesis of idiosyncratic 
drug reactions. The test is based on the hypothesis that idiosyncratic reactions develop as 
a result of imbalance between generation of toxic reactive metabolites (metabolic 
activation or toxication) and detoxication capacity which leads to accumulation of toxic 
metabolites (the “reactive metabolite” hypothesis).[4, 42-44] In this test, lymphocytes are 
used not as immunogenic cells but rather as easy to obtain surrogate target cells.
[41]
 The 
procedure for the test entails incubation of PBMCs isolated from the patient with the 
culprit drug in the presence of phenobarbital-induced mouse, rat or rabbit liver 
microsomal 9,000 x g supernatant fraction (S9), as a source of cytochrome P450 (CYP) 
monooxygenase activity). 
CYP activity in the rodent (or sometimes human) liver preparation is 
hypothesized to oxidize drug to its active (cytotoxic) metabolite(s). Lymphocytes contain 
enzymes that are required for drug detoxication including epoxide hydrolases (EHs) and 
glutathione S-transferases (GST) and any genetic defect in the function of these enzymes 
is phenotypically expressed in these cells.
[1]
 The % of cell death is then determined using 
different methods for assessing cell death (e.g., trypan blue exclusion or with a 
tetrazolium dye, for example by the MTT method). Cell death is assumed to reflect the 
vulnerability of the cells to the toxic effects of the drug which is hypothesized to indicate 
the susceptibility of the patient to develop hypersensitivity reactions to the parent drug 
and its reactive metabolite(s), presumably via differences in detoxication capacity and 
immune processing.  
    
 
 
53 
 
 
 
 
 
 
 
Fig.2. Steps of the lymphocyte transformation test (LTT). HBSS = Hanks balanced salt 
solution; PBMCs = peripheral blood monocytes; PBS = phoaphate buffered saline; RBCs 
= red blood cells; RPMI = Roswell Park Memorial Institute medium. 
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 Aromatic anticonvulsants are excellent examples of metabolically activated 
cytotoxicants, metabolized, primarily by hepatic CYP isozymes into reactive electrophilic 
arene oxide metabolites.[5] These unstable and highly reactive intermediate metabolites 
are readily detoxified by EH and/or GST enzymes usually to non-electrophilic products 
(dihydrodiols and S-glutathione conjugates, respectively)
[45, 46]
 
Although the same cell model (isolated PBMCs) is used in both types of assay, LTT 
and LTA are completely different approaches to the diagnosis of AHS. Whereas the 
former detects the in vivo immunological generation of drug-specific T-lymphocytes used 
as a sign of hypersensitivity, the latter detects genetic defects that lead to accumulation of 
toxic metabolites which are assumed to be a major factor in the etiology of drug 
hypersensitivity in addition to possible differences in cell death. Because the two tests use 
the same cell model and have similar nomenclature, it is not uncommon for individuals to 
confuse the LTT for LTA or vice versa
[47]
 or to use different nomenclature to describe 
these tests.
[2, 48, 49]
 
3.2. Research Methodology 
In order to evaluate the clinical usefulness of these tests in diagnosis of AHS, we 
performed a systematic literature search using three major biomedical citation databases, 
PubMed, EMBASE and MEDLINE without any restriction on date from their 
commencement to the fourth week of May 2009 
3.2.1. Search strategies 
Search strategy I: the search was carried out using the key words “anticonvulsant” 
and “antiepileptic” in their singular, plural and truncated forms. These terms were also 
    
 
 
56 
 
 
 
 
 
Fig. 3. Steps of the lymphocyte stoxicity assay (LTA). MICs = microsomes; MTT = 3-
(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazoluim; NADPH = nicotinamide adenosine 
dinucleotide phosphate; PBMCs = peripheral blood monocytes; PBS = phosphate 
buffered saline; RBCs = red blood cells. 
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mapped to their medical subject headings (MeSH) terms. We also searched for individual 
aromatic anticonvulsant drugs including „carbamazepine‟, „phenytoin‟, „phenobarbital‟, 
„oxcarbazepine‟, „primidone‟, „lamotrigine‟, „felbamate‟ and „zonisamide‟ both as key 
words and as MeSH terms when available and the option „explode‟ was used. The 
obtained results were combined using „or‟. 
Search strategy II: In parallel, we used as key words „lymphocyte toxicity assay‟, 
„LTA‟, „lymphocyte toxicity test‟, „in vitro lymphocyte toxicity assay‟, „in vitro 
lymphocyte toxicity test‟, „lymphocyte transformation test‟, „lymphocyte stimulation 
test‟, „lymphocyte proliferation test‟, „LTT‟, „LST‟, „LPT‟, „drug-induced lymphocyte 
stimulation test‟ and „DLST‟. These terms were also mapped to their MeSH terms when 
available and the option „explode‟ was used.  
We then combined the results of both searches (search strategy I and search 
strategy II) using „and‟ (figure 4).  
Retrieved publications were manually reviewed and the following selection 
criteria were applied: (i) original articles are written in English; (ii) study is performed on 
human subjects; (iii) LTA or LTT was used to diagnose AHS due to one or more 
aromatic anticonvulsant drug(s); and (iv) contains sufficient technical data for scientific 
evaluation. 
Thirty-one articles from PubMed, 22 articles from MEDLINE and 28 from 
EMBASE were found that met our selection criteria. The search results from the three 
databases were then combined and duplicates were removed. The final number of 
included articles from the three databases was 48 articles. Thirty six articles used LTT 
    
 
 
59 
and 12 used LTA for the diagnosis of AHS (figure 4). Although single case reports were 
included in the review, none of these reports were used to calculate any of the tests 
epidemiological characteristics. 
3.3. Results 
3.3.1. The LTT in the Diagnosis of Anticonvulsant Hypersensitivity Syndrome (AHS) 
The use of the LTT in diagnosis of hypersensitivity to ACDs dated back to the 
early 1960s, but its use was almost always confined to experienced technicians in well-
equipped research centres, primarily for the purpose of investigating the mechanism of T-
cell-mediated reactions rather than diagnosis of drug allergy
[14, 15, 50-53]
 In addition, due to 
its low laboratory-to-laboratory reproducibility
[31, 54]
 and hard-to-interpret results,
[31]
 this 
test cannot be described as user friendly and requires a great deal of experience for 
interpretation of results. For this reason the test has not been translated into widespread 
clinical use. In fact, only a few research groups worldwide use this technique 
routinely.[31] 
Table (I) summarizes data from original publications where LTT has been used to 
investigate hypersensitivity reactions to anticonvulsants. Troost et al.
[55]
 directly 
addressed the issue of LTT usefulness in AHS diagnosis They collected data from 65 
patients who displayed a wide range of adverse effects of carbamazepine (CBZ). They 
compared the performance of the  patch test (PT) with the LTT and found that the LTT 
had a better positive predictive value than the PT (40% and 20%, respectively). However, 
the inclusion criteria for the AHS cases were not well described and medical history was 
the only evidence that incriminated the drug. Furthermore, the low positive predictive 
value of the PT for CBZ (20%) in this study may indicate that some of the cases included
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Fig. 4. Flow chart of literature search and retrieving process. 1 Search strategies 
„anticonvulsants‟ and „LTA and LTT‟ include all relevant medical subject heading and 
key words as described in section 2.1. AHS = anticonvulsany hypersensitivity syndrome. 
LTA = lymphocyte toxicity assay, LTT = lymphocyte transformation test. 
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were not typical CBZ-induced hypersensitivity reactions. This is supported by the fact 
that only 23% of the included patients displayed systemic manifestations and that 92% of 
them had only some form of mild skin reaction as an adverse event. 
In an attempt to determine the sensitivity and specificity of the LTT in diagnosis 
of allergy to different drugs,[37] files of 923 patients with possible hypersensitivity 
reactions to drugs were studied. These patients were classified based on their medical 
history, follow-up and provocation tests into four groups where drug allergies were 
“definite,” “probable,” “less probable” or “negative”. One hundred cases were considered 
to have a very high probability of drug allergy, of which 78 had a positive LTT. Only 3 of 
these 100 cases were attributed to ACDs (2 to CBZ and 1 to DPH). The 2 CBZ cases 
exhibited positive LTT tests whereas for the DPH case the LTT was negative. Although 
the chemistry of the drug in question appears to play a major role in determining the 
usefulness of the LTT, the overall specificity and sensitivity of this test in this study were 
found to be in the range of 85% and 76%, respectively. It is not known whether or not 
these numbers can be applied to ACDs. However, due to the fact that many different 
factors are involved in determining the final result of the LTT test as discussed below, 
one cannot generalize these figures to include all types of drugs taken under various 
conditions.   
Numerous factors have been found to affect the predictive value of the LTT in the 
diagnosis of drug hypersensitivity reactions. These factors include: the timing of the test 
in relation to the beginning of the reaction; the type of clinical manifestations caused by 
the drug; the nature of the suspected drug; and the test procedure itself. 
3.3.1.1. Timing of the test. 
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Performing the LTT during the adverse drug reaction may result in the high 
incidence of false negative test results due to the high rate of spontaneous T-cell 
proliferation that does not respond to any additional in vitro stimulation (refractory 
period).
[50, 55, 56]
 Houwerzijl and coworkers
[57]
 demonstrated the relationship between the 
timing of the test and its outcome. Sequentially testing a number of patients with 
hypersensitivity reactions to CBZ, they showed that this refractory period may extend up 
to 11 weeks from the time of the adverse reaction. This effect may be due to impaired T-
cell function as the predominant T-cell mitogen, PHA could not stimulate T-cells during 
this period[57] In contrast,
[58]
 Zakrzewska and Ivanyi obtained positive results when 
performing LTT on 6 of 9 patients within 2 weeks of the beginning of the adverse 
reaction. These authors attributed their results to the mild form of the adverse reactions 
(skin rash only) in their patients. In such cases, a shorter or no refractory period is 
expected due to the moderate degree of activation of T-cells.  
Although drug-specific T-cells have been isolated from patients decades after the 
time of the reaction,
[15]
 a positive LTT is not guaranteed if the test is performed later than 
3-4 years after the reaction. 
[31]
After remission from severe hypersensitivity drug 
reactions the frequencies of circulating drug-specific T-cells was estimated at 1:250 to 
1:5000 (from 1:2000 to 1:10,000 for ACDs) and this rate does not appear to be affected 
by time. These frequencies were higher than frequencies of T-cells that recognize a full 
antigen such as tetanus toxoid (TT).
[15]
 It is well documented that circulating drug-
specific T-cells may last for years or even decades
[15, 31, 59]
 after the insult but the length 
of this period may vary considerably for reasons not yet understood. 
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In a recent study designed to investigate the effects of timing and type of drug 
involved in adverse reactions on the utility of the LTT for diagnosis of drug 
hypersensitivity, Kano and colleagues
[60]
 followed 12 patients suffering from different 
types of drug-induced hypersensitivity reactions (i.e., macula-papular eruption, MP; 
Steven- Jonson syndrome, SJS; and AHS or DRESS). Six patients developed AHS as a 
result of taking aromatic ring-containing anticonvulsants (DPH, CBZ and phenobarbital; 
PHB). Only one of 6 patients showed a positive LTT when the tests were performed 
within one week of the onset of the reaction. However, all 6 patients gave positive LTT 
results when tested at a later time (ranging from 5 weeks to 1 year). Interestingly, patients 
with MP and SJS showed an opposite pattern where the stimulation indices (SI) levels 
decreased with time. In another study of one case of CBZ-induced hypersensitivity that 
involved pulmonary symptoms, fever, generalized maculopapular erythmatous skin 
eruptions and eosinophilia, the LTT performed during the course of the reaction was 
positive (SI = 2.2). However, when the test was repeated 3 months after recovery, a 
negative result was obtained.
[61]
  
In contrast, Wu et al.
[14]
 did not find any association between timing of the test 
and the strength of the response in a cohort of cases of hypersensitivity to CBZ. 
Specifically testing a patient < one month after the reaction resulted in a strongly positive 
LTT (SI up to 69.4). In the study, similar results were obtained when testing patients at 
84 and 180 months after the event, similar to Beeler‟s results[15] at 4 and 19 months after 
the reaction. Houwerzijl et al.
[57]
 showed that maximum SI values are obtained if the test 
is performed 10 to 20 weeks after the beginning of the reaction, after which the SI values 
start to decline over time. 
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It appears that during the course of the adverse reaction drug-specific T-lymphocytes 
go through three different stages:  
1. A highly reactive stage (very strong response) that shows spontaneous 
proliferation during which the cells do not respond to any additional in vitro 
stimulation.
[31, 60]
 This stage appears to last for the first 1-4 weeks after the 
adverse event depending on the strength of the initial reaction.
[57]
 Stronger 
reactions usually result in longer “refractory periods” than weaker ones. 
2. An apparently long stage where drug-specific T-cells can be detected in 
peripheral blood and are responsive to an in vitro stimulation (strong response). 
This stage starts at the remission of the reaction and may last for years and 
sometimes for decades.
[31]
  
3. A final stage, where no drug-specific T-cells can be detected in peripheral blood 
(weak response). This does not mean that the patient is desensitized to the drug or 
is able to tolerate it. In fact, a severe reaction may develop again once the patient 
is exposed to the culprit agent.
[15, 31]
 
The so-called refractory period has been attributed to two mechanisms: 1) the 
circulating peripheral T-lymphocytes are at their maximum activation and do not 
respond to any further stimulation in the presence of the drug; and 2) drug-specific T-
lymphocytes are selectively recruited to the affected target organs leading to a 
deficiency of these cells in peripheral blood.
[55, 57, 64]
 It has also been observed that 
PBMCs isolated from patients during the hypersensitivity episode are characterized 
by a high proliferation rate, presumably related to their recent exposure to the culprit 
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drug (in vivo). These activated T-cells cannot be further stimulated by exposure to the 
drug or PHA in vitro. 
3.3.1.2. Clinical manifestation of the reactions. 
Hypersensitivity reactions to drugs can manifest in a wide range of distinct clinical 
symptoms including morbilliforme or bullous exanthema, urticaria, as well as 
involvement of other internal organs and including fever, blood cell dyscrasia hepatitis, 
nephritis and interstitial lung disease.
[67, 83]
 Severe forms of AHS include erythema 
multiform (EM), SJS and toxic epidermal necrolysis (TEN).
[84]
 Some of these reactions 
cannot be listed under any known classification of immune-mediated diseases. T-cell-
mediated drug allergy can take different forms and utilize a variety of mechanisms 
including activation of different clones of T-cells and secretion of different types of 
mediators.
[85]
 In some cases such as in patients with drug-induced SJS, the proliferative 
response of the drug-specific T-cells was found to be low despite the high level of 
secreted cytokines.
[15]
 This can affect the ability of T-cell proliferation tests such as the 
LTT to detect low levels of circulating drug-specific T-cells, however, in this particular 
context measuring cytokines secretion as a readout system for T-cell activation can be 
more sensitive than the conventional LTT.
[32]
 
Neukomm et al. 
[67]
 did not find any correlation between the strength of the LTT 
result (SI) and the type of the adverse drug reaction, but showed positive LTT results for 
a wide variety of reactions including IgE-mediated reactions. It is quite unexpected that 
an in vitro test such as the LTT can give positive results in all cases where drug-induced
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Table I. Summary of data from original work that used the lymphocyte transformation test (LTT) to investigate 
hypersensitivity reactions to aromativ anticonvulsants. 
Type of study 
No. of 
patients 
No. of 
controls 
Drug
a
 
Conc. (% 
unless 
otherwise 
indicated) 
Time
b
 Read-out 
Frequency 
of positive 
result (%) 
Year/ 
Reference 
Case series 2 5 carbamazepine 1, 10, 100 2 M, 14 M 
CD69  
3
H-T 
2/2  
 1 5 Phenytoin 1, 10, 100 2 M, 14 M 
CD69  
3
H-T 
1/1 2008 [62] 
Case series 4 4 carbamazepine 1/50-1/100 
< 1mo 3
H-T 
2/4 
 
>  1 mo 4/4 
 1 4 Phenytoin 1/50-1/100 
< 1 mo 3
H-T 
0/1 
 
>  1 mo 1/1 
 1 4 Phenobarbital 1/50-1/100 
< 1 mo 3
H-T 
0/1 
2007[60] 
>  1 mo 1/1 
Case series 7 11 Phenytoin 50ug/ml 1 mo -4Y 
CFSE 7/7 (100%) 
2007[63] 
IFN-γ 5/7 (71.4%) 
Case report 1 0 Phenytoin 200 µg/ml 2 Wk 
3
H-T 0/1  
      CFSE 1/1 2006[34] 
Case series 8 32
c
 carbamazepine 10-200 µg/ml 1-120 mo 
3
H-T 2/8 (25%)  
 1 32 Oxcabazepine 10-200 µg/ml 1-120 mo 
3
H-T 1/1  
 1 32 Phenobarbital 10-200 µg/ml 1-120 mo 
3
H-T 1/1 2006[64] 
Case series 12 0 carbamazepine 10-100 1-229 mo 
3
H-T 
11/12 
(92%) 
 
 1 0 Oxcabazepine 10-100 23 mo 
3
H-T 1/1 2006[14] 
Case series 1 1 Phenytoin 10, 50 µg/ml 19 mo 
3
H-T 1/1 
 
CFSE 1/1 
 1 1 carbamazepine 10 µg/ml 4 mo 
3
H-T 1/1 2006[15] 
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Type of study 
No. of 
patients 
No. of 
controls 
Drug
a
 
Conc. (% 
unless 
otherwise 
indicated) 
Time
b
 Read-out 
Frequency 
of positive 
result (%) 
Year/ 
Reference 
CFSE 1/1 
Case series 1 20 Phenytoin 20% 
> 6 Wk Aft. 
Rec 
3
H-T 1/1  
 1 20 carbamazepine 12.5% 
> 6 Wk Aft. 
Rec 
3
H-T 1/1 2005[65] 
Case report 1 0 carbamazepine NA 29D NA 0/1 2003[66] 
Cohort Study 4 8 Lamotrigine 1-100 µg/ml 5-10Y 
3
H-T 3/4 (75%) 2003[51] 
Cohort Study 5 8 carbamazepine 1-100 µg/ml 1-72 mo 
3
H-T 5/5 (100%) 2003[53] 
Cohort study 2 2 carbamazepine 1-100 µg/ml N/A 
3
H-T 
IL-5 
2/2 (100%) 2002[32] 
Cohort Study 2 >3 carbamazepine 10 µg/ml 6-8 Wks 
3
H-T 2/2 (100%) 2001[67] 
Case report 1 0 Zonisamide 3,10 µg/ml N/A 
3
H-T 1/1 2001[68] 
Case series 2 2 carbamazepine 1,10,100 µg/ml 4-6 Wks 
3
H-T 1/1 2001[50] 
Case report 1 0 Phenytoin 0.1-1000 µg/ml 101 D 
3
H-T 1/1 2000[69] 
Case report 1 0 Phenytoin N/A AFT REM 
3
H-T 1/1 2000[70] 
Case report 1 1 
Phenytoin / 
Phenobarbital 
N/A 3 & 16 D 
3
H-T 1/1 2000[71] 
Case report 1 2 Lamotrigine 0.1-100 3-4 mo 
3
H-T 1/1
d
 2000[72] 
Case report 1 7 carbamazepine 10 N/A 
3
H-T 1/1 1999[73] 
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Type of study 
No. of 
patients 
No. of 
controls 
Drug
a
 
Conc. (% 
unless 
otherwise 
indicated) 
Time
b
 Read-out 
Frequency 
of positive 
result (%) 
Year/ 
Reference 
Case series 2 0 carbamazepine 1, 10, 100 N/A 
3
H-T 1/1  
 1 0 Phenytoin 1, 10, 100 N/A 
3
H-T 0/1 1997[37] 
Case report 1 1 Lamotrigine 0.1-50 µg/ml 3Wks & 1 mo 
3
H-T 1/1 1997[74] 
Case series 65 21 carbamazepine 5, 10, 15 N/A 
3
H-T 
26/65 
(40%) 
 
 64 21 Oxcarbazepine 5, 10, 15 N/A 
3
H-T 
12/64 
(19%) 
1996[55] 
Case report 1 5 carbamazepine 42, 84, 168 µM 2 Wks 
3
H-T 1/1 1996[56] 
Case series 1 0 carbamazepine 10, 100 1 mo 
3
H-T 1/1  
 1 0 Phenytoin 10, 100 1 mo 
3
H-T 1/1 1995[75] 
Case report 1 0 carbamazepine N/A Aft. Rec   
3
H-T 0/1  
 1 0 
10,11-carbamazepine 
Epoxide 
N/A Aft. Rec   
3
H-T 1/1 1995[76] 
Case report 1 6 carbamazepine 100 µg/ml N/A 
3
H-T 0/1? 1994[77] 
Case series 1 1 Phenytoin 0.01-10 µg/ml 30 D 
3
H-T
 
1/1 1994[78] 
Case report 1 0 carbamazepine 25 µg/ml N/A 
3
H-T 1/1 1993[79] 
Case report 1 0 Phenytoin N/A 2 mo 
3
H-T 1/1 1989[80] 
Case series 9 41 carbamazepine 1-100 1-104 Wks 
14
C-T 9/9 (100%)  
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Type of study 
No. of 
patients 
No. of 
controls 
Drug
a
 
Conc. (% 
unless 
otherwise 
indicated) 
Time
b
 Read-out 
Frequency 
of positive 
result (%) 
Year/ 
Reference 
 6 41 
10,11-carbamazepine 
Epoxide 
1-100 1-104 Wks 
14
C-T 1/6 (16.7%)  
 6 41 Oxcarbazepine 1-100 1-104 Wks 
14
C-T 1/6 (16.7%) 1988[58] 
Case report 1 8 carbamazepine 3,10,30 µg/ml 8 Wks 
3
H-T 1/1 1984[81] 
Case series 6 10 carbamazepine 3,10,30 13Wk-5Y 
3
H-T 6/6 (100%)  
 1 10 Phenytoin 3,10,30 13Wk-5Y 
3
H-T 1/1 1977[57] 
Case report 1 0 carbamazepine 25 µg/ml DUR 
3
H-T 1/1 1975[61] 
Case series 2 25 carbamazepine 10 2-10 mo 
3
H-T 1/2 1971[82] 
Case report 1 3 Phenytoin 20 10 mo 
3
H-T 1/1 1964[23] 
[a]: The suspected drug causing the reaction as suggested by at least the medical history. 
[b]: Time elapsed between the reaction and the test. 
[c]: In this particular study 26.5% of control was positive. 
[d]: positive skin patch test 
Abbreviations: 3H-T = 3H-Thymidine incorporation assay, AC  = anticonvulsant, Ace  = acetone, Aft. Rec  = after 
recovery, AHS  = anticonvulsant hypersensitivity syndrome, A.R. = after remission, CFSE = caboxyfluorescein 
succinimidyl ester dilution assay, Cr.Tab = crushed tablet, DUR = during, Eth = ethanol, mo = month, Meth = 
methanol, Petr = petrolatum, Sal = saline, Wat = water, Wk = week, Y = year. 
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reactions are attributed to different agents and mediated by distinct immunological 
mechanisms. For instance, haptens and pro-haptens such as β-lactam antibiotics require 
processing before they are able to activate T-cells whereas other drugs such as CBZ, 
lamotrigine (LMG) and SMX and their metabolites are thought to directly activate T-cell 
through other mechanisms.
[86-89]
 
Nevertheless, in most of the clinical syndromes associated with aromatic 
anticonvulsant use (e.g., generalized macula-papular exanthema, bullous reactions, multi 
organ DRESS syndrome, etc.) the LTT is frequently positive.
[31]
 As mentioned earlier, 
severe bullous reactions such as TEN rarely yield a positive LTT, and the reason behind 
this is unknown. Romano et al.
[64]
 tested 8 patients with a history of hypersensitivity 
reactions to CBZ (6 patients with macula-papular exanthema (ME), one with bullous 
exanthema (BE) and one with SJS). All 6 cases with ME yielded negative LTT results 
despite a positive patch test in 4 of them. On the other hand, the test was positive with the 
other two cases (BE and SJS). Six ME patients were tested within 2 years of the adverse 
reaction whereas the BE and SJS cases were tested 6 and 12 years later, respectively.
[64]
 
The LTT detects circulating peripheral drug-specific T-lymphocytes. Such 
aromatic anticonvulsant reactive T-cells have been cloned and characterized in multiple 
previous studies.
[14, 15, 51, 53, 63, 90]
 If, for whatever reason, the pathophysiology of the 
disease does not involve a high frequency of circulating drug-specific T-cells, the LTT 
will not confirm the diagnosis. The mediocre sensitivity of the LTT in the diagnosis of 
AHS (around 70%) has provoked uncertainty about the real pathophysiology of this 
disorder and whether it actually exists. There is increasing evidence on the heterogeneity 
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of AHS reactions and that they might be mediated by distinct yet unidentified 
pathophysiology mechanisms.
[43, 44, 91, 92]
  
Recognition of the suspected drug by the isolated peripheral lymphocytes is 
another dilemma as antigen processing does not seem to be required for T-cell activation 
in vitro. This can be partially explained by a relatively recently introduced paradigm, the 
“p-i" concept. This term stands for “direct pharmacological interaction of drugs with 
immune receptors” and assumes that a chemically inert drug can non-covalently interact 
with receptors on the immune cells and activate them without being a full antigen.
[87]
 
This interaction that involves only T-cells may explain why drugs such as CBZ elicit only 
T-cell-mediated adverse effects while haptens (β-lactam antibiotics) are able to cause all 
sorts of idiosyncratic reactions including anaphylaxis. In fact, some investigators have 
found the LTT to be useless in the diagnosis of reactions such as pneumonia caused by 
minocycline, bucillamine, amoxicillin and clindamycine
[93-95]
 or hepatitis due to herbal 
medicines.
[94]
 This probably is because these reactions were mediated by other 
mechanism(s). However, in cases with multiple organ involvement including liver 
dysfunction, the LTT is more likely to yield positive results.
[72]
 This suggests that several 
different immunological mechanisms underlie the apparent clinical manifestations. 
3.3.1.3. The specific drug. 
The LTT has given positive results with most aromatic anticonvulsant drugs 
including DPH, CBZ, oxcarbazepine (OCBZ), PHB, LAM and zonisamide (ZIM) with 
sensitivity ranging between 25% and 100%.
[14, 53, 55, 63, 68, 96]
 However, issues related to the 
chemistry and pharmacology of the tested drug may limit the outcome of the LTT. One 
such problem may be the solubility of the tested drug in the incubation medium. The 
    
 
 
73 
majority of the lipophilic aromatic anticonvulsant are not water soluble and require 
solubilisation in an organic solvent (e.g., dimethyl sulfoxide, ethanol or propylene 
glycol). It is important to ensure that the final concentration of the solvent in the medium 
is not cytotoxic. In addition some researchers found that it is necessary to sonicate the 
drug solution to enhance its solubility.
[60]
 
In addition, some drugs may cause non-specific activation or deactivation of 
PBMCs resulting in false positive or false negative LTT results. Higher concentrations of 
CBZ or DPH cause cytotoxicity and kill PBMCs, an effect that may mask any expansion 
of lymphocytes, resulting in low SI levels (false negative). Therefore it is essential to 
examine the effects of the used drug concentration on cells stimulated by the non-specific 
mitogen PHA.
[31]
  
The effect of coadminstrated systemic corticosteroids on test results is 
controversial. Although some researchers state that systemic administration of more that 
0.2mg/kg of prednisolone may interfere with the LTT,
[31]
 others have found no such 
effect.
[60]
 
3.3.1.4. Test procedure and read-out system. 
The most evident pitfalls of this in vitro diagnostic test are its complicated 
procedure and lack of standardization.
[31]
 Attempts to simplify the test procedure and 
improve its reproducibility have been described for decades
[32, 34, 37, 58, 62]
 however, the 
long-sought simple and reproducible LTT is not yet achievable. The common challenge 
among aromatic anticonvulsants is their need to be enzymatically activated  to more 
reactive metabolites to elicit their presumed HS reactions.
[42, 49]
 This observation has led 
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some researchers to use liver microsomes to increase the test sensitivity.
[97]
 Others have 
also used ex vivo serum from healthy volunteers taking the drug.
[78]
 However, these 
approaches did not improve the sensitivity of the test.  
Another important aspect of the LTT is the read-out method. Traditionally T-cell 
proliferation is measured by [
3
H]thymidine uptake which has proven to be very 
reproducible. Other methods to detect T-cell activation including such synthesis and 
release of IL-5, IL-10, IFN-γ and CD69 have also been used and shown to improve the 
sensitivity of the test.
[62, 98]
 Other workers have also used increased secretion of soluble 
Fas ligand (sFasL) as a read-out or biomarker and found this protein to be significantly 
increased in patients with CBZ-induced blistering diseases (SJS/TEN).
[13, 99]
 Granulysin, 
a cytolytic and proinflammatory protein excreted by activated cytotoxic T lymphocytes 
(CTLs), natural killer (NK) and NKT cells. 
[100]
 It was shown to be a key mediator of 
keratinocyte apoptosis in severe bullous reactions and to be present in high 
concentrations in blister fluids in patients with CBZ- and DPH-induced SJS and TEN.
[101]
 
Expression of such mediators can be of clinical value in diagnosis or determining the 
prognosis of drug-induced bullous reactions 
3.3.2. Lymphocyte toxicity assay (LTA): 
The use of the LTA in diagnosing AHS dates back to the early 1980s.
[40]
 
However, except for 4 major studies,
[1, 102-104]
 the lack of large scale application is quite 
obvious. Shear and Spielberg
[1]
 studied 53 patients with a medical history suggesting 
AHS due to DPH, CBZ or PHB as well as 49 unexposed healthy controls and 10 DPH-
exposed healthy controls. Symptoms included fever, skin rash (varied in severity from 
generalized exanthema to TEN), eosinophilia, atypical lymphocytosis and internal organ 
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involvement (liver, kidney, thyroid or lung). The performance of the LTA as a diagnostic 
test in this cohort of patients was excellent, with only 2 false positive and one false 
negative results in patients with hypersensitivity reactions to PHB. Naranjo et al.
[104]
 
tested 51 patients with highly likely diagnosis of AHS to DPH, CBZ or PHB and 
estimated the sensitivity and specificity of the LTA to be 99% and 75%, respectively. 
However, only 8 drug-tolerant patients were included in the study, rendering precise 
determination of the specificity of the test impossible. On the other hand, the lack of a 
gold standard against which results of the LTA can be validated has always made these 
numbers merely an estimate.  
In another study by Neuman and colleagues the LTA was used to diagnose AHS 
in 86 patients, 62 of them developed an adverse reaction as a result of taking aromatic 
anticonvulsants.
[102]
 Although the inclusion criteria for the cases were not well defined, 
the sensitivity and specificity of results of the LTA in the diagnosis of AHS were 
estimated to be 98% and 89%, respectively and the positive and negative predictive 
values were found to be 90% and 64%, respectively. To evaluate cross reactivity among 
old aromatic anticonvulsant (DPH, CBZ and PHB) and zonisamide (ZNS), a new 
aromatic anticonvulsant, Neuman et al.[103] tested 20 AAC-hypersensitive patients and 
20 AAC-tolerant patients using the LTA. Tested patients had exhibited a broad spectrum 
of AHS manifestations including fever, skin rash, internal organ involvement, SJS and 
TEN). The authors estimated the sensitivity and specificity of LTA in this cohort of 
patients to be 92.9% and 99.1, respectively. 
In a technician blinded, hospital based controlled study, Dwivedi et al.
[105]
 tested 
11 patients with AHS to DPH. Five patients had SJS, 4 had erythrodermic eruption, 1 had 
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morbilliform eruption and 1 lichenoid eruption. The authors also tested 11 healthy and 
DPH-tolerant volunteers as controls. All 11 patients gave positive LTA (% of cell death 
ranged between 7% and 26% as compared to 2.6% and 3.5% for controls). It is of note 
that in this study cells from patients with a severe form of AHS (SJS) exhibited a higher 
percentage of cell death (12-26%) than milder forms (7-13%) and that was related to a 
greater deficiency in expression or effectiveness of detoxifying enzymes.  
The LTA is simpler and has a less complicated procedure than the LTT, not 
requiring radioactive reagents. However, the sensitivity and specificity of the LTA in 
determining the culprit drug in AHS have not been extensively evaluated, mainly due to a 
lack of strict inclusion criteria in the reported cases. A systemic rechallenge could be a 
definitive proof of drug culpability but this is ethically unacceptable because of the 
possibility of danger to the patient. 
3.4.2.1. Technical considerations for the LTA 
As outlined earlier, the basic principle of the LTA is to generate in tube the presumed 
cytotoxic metabolite(s) of the suspected drug in the presence of the surrogate cell model 
and to measure lymphocyte susceptibility to metabolite-induced cell death. This process 
depends largely on the test procedure and reagents used. Table (3) summarises the 
different steps to be considered in optimizing the performance of the LTA.  
For example, contamination of isolated PBMCs with platelets can affect lymphocyte 
function and activity in vitro
 [109, 110]
 and may also modify the evaluation of cell death by 
the MTT method. Platelets have unusually high numbers of mitochondria (the source of 
the succinate dehydrogenase enzyme that converts MTT to blue formazan dye) and their 
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presence in the medium can compromise the signal (unpublished data). A number of 
methods have been introduced to prepare platelet-free PBMCs, 
[109, 111-114]
 although this 
increases the cost and complexity of the test.  On the other hand, the usage of platelets as 
a surrogate model in place of PBMCs could be advantageous as platelets are easier to 
isolate and more abundant in peripheral blood than PBMCs. They were found to respond 
with the same way as PBMCs to different chemical insult and platelets from drug 
hypersensitive patients were found to be more susceptible to cell death induced by the 
suspected drug than platelets from healthy volunteers who have never exposed to the 
drug (under preparation).  
 In addition, the in vitro metabolic activation system (liver microsomes) plays an 
important role in the success of the test especially when testing drugs such as those 
aromatic anticonvulsants whose toxic metabolites are still unknown. Differences among 
species in terms of metabolic activation of drugs by CYP isozymes
[115]
 and their relative 
levels expression in untreated and induced microsomal systems should be considered 
when performing the LTA. The incubation conditions of the surrogate cells with the 
suspected drug and liver microsomes should be standardized. The pH of the medium have 
a tremendous effect on the viability of PBMCs (unpublished data), therefore, the pH 
should be adjusted to 7.2-7.4 just prior to performing the test. Other additives such as 
fetal bovine serum (FBS) are also essential to the viability of the cells and should be 
standardized.  
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Table II. Summary of data from original work that used lymphocyte toxicity assay (LTA) to investigate idiosyncratic 
reactions to aromatic anticonvulsants. 
Type of study 
No. of 
patients 
No. of 
controls 
Drug
a
 Concentration Time
b
 
Liver 
microsome 
species 
Induction 
with 
phenobar
bital 
Endpoint 
measure
ment 
Frequency of 
positive result 
(%) 
Year/ 
Reference 
Cohort study 20 20 
Phenytoin 
Carbamazepine 
Phenobarbital 
Zonisamide 
N/A N/A mouse + MTT SEN=92.9% 2008[103] 
Case report 1 1 Lamotrigine 0-32 µg/ml 2 mo N/A ? N/A 1/1 2006[47] 
Case series 11 11 Phenytoin 0-32 µg/ml N/A mouse + TB 11/11 (100%) 2004[105] 
Case report 1 0 Phenobarbital 0-32 µg/ml 70 D mouse + TB 1/1 2004[106] 
Cohort study 62 24 
Phenytoin 
Carbamazepine 
Phenobarbital 
Lamotrigine 
N/A N/A mouse + MTT  SEN=98%  
 62 24 N/A N/A mouse + TB SEN=91% 2000[102] 
Cohort study 51 0 
Phenytoin 
Carbamazepine 
Phenobarbital 
N/A N/A mouse + TB 49/51 (96.1%) 1994[104] 
Case report 1 6 Carbamazepine 50 µmol/L N/A mouse + TB 1/1 1994[77] 
Case series 3
c
 59 Phenytoin 62.5 µmol/L N/A mouse + TB 3/3 (100%) 1991[107] 
Case series 7 17 Carbamazepine 50 µM N/A
d
 Human - TB 7/7 (100%)  
 1 17 
Carbamazepine 
Oxcarbazepine  
50 µM N/A Human - TB 1/1 1991[108] 
Cohort study 34 59 Phenytoin 62.5 µM N/A mouse + TB 34/34 (100%)  
 25 59 Carbamazepine 62.5 µM N/A mouse + TB 21/25 (84%)  
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Type of study 
No. of 
patients 
No. of 
controls 
Drug
a
 Concentration Time
b
 
Liver 
microsome 
species 
Induction 
with 
phenobar
bital 
Endpoint 
measure
ment 
Frequency of 
positive result 
(%) 
Year/ 
Reference 
 22 59 Phenobarbital 62.5 µM N/A mouse +  TB 21/22 (95.5%) 1988[1] 
Case series 2 20 Phenytoin 
31-125 
µmol/L 
After 
recove
ry 
mouse + TB 2/2 (100%) 1986[39] 
Case series 3 17 Phenytoin 
31, 62, 125 
µM 
After 
recove
ry 
mouse + TB 3/3 (100%) 1981[40] 
[a]: The suspected drug causing the reaction as suggested by at least the medical history. 
[b]: time elapsed between the reaction and the test. 
† : In this particular study 26.5% of control was positive. 
[c]: siblings from the same family. 
[d]: only two patients were tested acutely and there was no significant difference. 
Abbreviations: E.P.= end point measurement, Ind.= induction with phenobarbitone, M = month,  MIC Sp= liver microsome 
species, TB= trypan blue, Wk = week, SEN = Sensitivity, Y = year. 
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Table (3): Opportunities for technical improvement of the lymphocyte toxicity assay 
(LTA). 
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Isolation and purification of surrogate model cells (PBMCs) 
Reduction of the number of contaminating platelets 
Use of platelets as a surrogate model 
The metabolic activation system 
Species difference in liver microsomes metabolic activity (human vs animals). 
Use of induced vs. non-induced microsomes 
Incubation conditions 
Incubation time 
Buffers and additives 
End-point and measurement methods 
Method of measurement of cell death 
Other end-points (e.g., expression of other cell injury markers) 
PBMCs=Peripheral blood monocytes 
 
 
 82 
 
 
Cell death is the ultimate response of vulnerable cells exposed to the offending drug 
as an insult. However, it is a gross measure of the cellular and sub-cellular events that 
occur and may vary depending on the tested drug and the incubation conditions.
[116]
 In 
this regard, cell death is unlikely to be the best end point to indicate cell response to a 
toxic insult. Finally, defining and obtaining the ultimate in vivo toxic metabolite(s) of the 
offending drugs and their direct in vitro  testing will have a strong impact on the 
predictability of the results of the LTA as the complicated metabolic activation step(s) 
will be eliminated. This has been proven to be true in testing patients hypersensitive to 
sulphonamides where the reactive metabolites can be tested directly to assist in test 
validation.
[117]
 
3.4. Discussion 
AHS is a rare but potentially lethal disorder. One of most challenging aspects of this 
disease is the difficulty to establish solid diagnosis in a timely manner.
[2, 8, 118-121]
 Lack of 
or misdiagnosis may result in increased morbidity, mortality and extended 
hospitalization.
[122, 123]
 Ten to 27% of patients with epilepsy discontinue their first anti-
epileptic drug because of the development of adverse reactions.
[124]
 Aromatic 
anticonvulsant drugs such as DPH, CBZ, PHB and LMG are linked to a relatively high 
risk of for development of hypersensitivity reactions.
[125]
 CBZ was found to be the 
commonest cause of severe forms of AHS (i.e., SJS and TEN).
[126]
 
The diagnosis of AHS entails two main processes: first, establishing diagnosis of 
the hypersensitivity reaction, usually from a series of clinically similar differential 
diagnoses, and second, identifying the culprit drug, potentially among a number of other 
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concomitantly prescribed innocent ones. Numerous diagnostic tests are available and 
have been attempted for the diagnosis of drug hypersensitivity reactions; however, their 
epidemiological qualities are dependent on the type of reaction (immediate versus 
delayed reactions) and type of drug, and choosing the best test for a specific drug or drug 
class can be quite challenging.
[7, 8, 37]
  
The LTT and LTA are two different approaches for AHS diagnosis and may 
complement each other as a battery of diagnostic tests that can also include in vivo tests 
such as the patch test and systemic rechallenge. The LTA may predict the susceptibility 
of patients to develop AHS based on a genetic deficiency in their cellular defence 
systems against toxic reactive drug metabolite(s), whereas the LTT may confirm the 
development of AHS by detecting peripherally circulating drug-specific T-cells. It is 
evident that these tests lack standardization and large scale validation to determine their 
appropriations in terms of sensitivity and specificity in addition to positive and negative 
predictive values.
[31, 37, 48]
 
The sensitivity and specificity of the LTT in diagnosis of drug allergy has been 
estimated to range from 56% to 78% and from 85% to 93%, respectively although these 
estimates are generally based on cases of allergy to β-lactam antibiotics and cannot be 
extended to other types of drugs.
[37, 59]
 In the diagnosis of AHS due to aromatic 
anticonvulsants (AACs) the LTT has frequently shown a sensitivity between 71% to 
100%
[14, 51, 53, 57, 58, 62, 63, 67]
 but this range also as low as 19% to 40%.
[55, 64, 65, 76] 
Estimates 
of specificity, however, seem to be quite good (close to 100%).
[51, 53]
 Nevertheless, one 
must always keep in mind that these estimates have been calculated in the absence of a 
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diagnostic gold standard, which may explain the considerable variability in these 
numbers. 
AHS has a broad range of clinical manifestations
[127]
 reflecting differences in the 
underlying pathophysiology.
[91, 128]
 If the LTT is able to detect circulating drug-specific 
T-cells, it is logical to expect that other “non-T-cell-mediated” reactions will not be 
detected using this approach.  Ironically, the LTT gave positive results with IgE-mediated 
type I reactions which also imply a role for T-cells in these types of reactions.
[67]
 In vitro 
tests detecting antigen-specific IgE antibodies are also available and might be expected to 
be more sensitive for these types of reactions.
[8]
  
Reviewing publications on the use of the LTA as a diagnostic tool for AHS has revealed 
a range of sensitivity between 85 to 100% with well documented AHS cases, with 
satisfactory negative and positive predictive values. The LTA has also been shown to 
possess good sensitivity in cases involving AHS due to sulphonamides
[117, 129-131]
 and 
valproic acid.
[132]
 
3.5. Conclusion 
Analysis of peripheral blood lymphocytes has been a “promising” diagnostic tool 
for HAS for several decades. It appears that without further understanding of the 
mechanisms underlying the pathophysiology of AHS and how specific drugs and 
metabolites differentially affect these mechanisms that the development of more reliable 
tools for AHS diagnosis will be compromised. Consequently, in the absence of further 
research the predictability of these tests will remain questionable and they are unlikely to 
be utilized on a large scale. 
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Chapter 4: Predictive Value of the Lymphocyte Toxicity Assay in Diagnosis of Drug 
Hypersensitivity Syndrome 
 
This chapter has been published previously: 
 
Elzagallaai AA, Jahedmotlagh Z, Del Pozzo-Magaña BR, Knowles SR, Prasad AN, Shear 
NH, Rieder MJ, Koren G. Predictive value of the lymphocyte toxicity assay in the 
diagnosis of drug hypersensitivity syndrome. Mol Diagn Ther. 2010 Oct 1;14(5):317-22 
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4.1. Introduction 
The term adverse drug reaction (ADR) is defined as any noxious and unintended 
response to a drug that occurs at a dose normally used in man for prophylaxis, diagnosis 
or therapy.
[1]
 Most ADRs are predictable, dose-dependent and related to the 
pharmacological action of the drug (Type A), accounting for 75-80% of all reported 
ADRs. The remaining 20 to 25% are defined as Type B-ADRs which are unpredictable, 
unrelated to the known primary pharmacological action of the drugs and do not have a 
clear dose-dependency.
[2, 3]
 As they are patient-specific and unpredictable this type is also 
titled idiosyncratic drug reactions (IDRs). Typically IDRs occur in a small fraction of 
patients at the normal therapeutic dose and are unrelated to the primary pharmacological 
action of the drug.
[4]
 Unfortunately, the underlying mechanisms of IDRs are poorly 
understood although a large portion of IDRs are believed to be immune-mediated, at least 
in part, as delay in onset and rapid occurrence upon rechallenge are typical.
[5]
 Drug 
hypersensitivity syndrome (DHS) is considered one type of immune-mediated IDRs, 
characterized by constellation of signs and symptoms that develop in susceptible patients 
following exposure to certain drugs.
[6]
 It is most commonly associated with the use of 
NSAIDs, aromatic anticonvulsants (AACs), antibiotics and sulfonamides 
antimicrobials.
[7]
  
It has always been a challenge to establish the diagnosis of DHS due to lack of a 
safe and reliable diagnostic test and because of its variable clinical picture. Another 
challenge is the fact that, with the exception of fixed drug eruption (FDE), it can be 
mimicked by other non-drug related illnesses (e.g., bacterial or viral infections).
[4, 8, 9]
 In 
addition to the importance of identifying susceptible patients to establish safe clinical 
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practice it is essential not to falsely label a patient as hypersensitive to a drug which could 
be otherwise therapeutically useful. This is especially important in cases where 
alternative therapy is more risky or less effective (e.g., first line therapy for epilepsy or 
allopurinol for gout). This warrants the development of safe and reliable test to confirm 
diagnosis and identify the culprit drug. 
We have recently performed systematic reviews to evaluate the usefulness of 
different in vivo and in vitro diagnostic tests in the diagnosis of DHS due to aromatic 
anticonvulsant drugs.
[10, 11]
 These tests included the skin patch test (PT), the lymphocyte 
transformation test (LTT) and the lymphocyte toxicity assay (LTA). It was quite evident 
that the negative and positive predictive values of these tests were not clear, their 
usefulness in clinical practice is controversial and that more research is needed to prove 
or disprove their clinical usefulness. Systemic rechallenge or provocation test is 
considered the „gold standard‟ in diagnosis of DHS. However, this approach is not 
always ethically plausible due to potentially severe reactions that may develop.
[8, 12, 13]
 
The lymphocyte toxicity assay (LTA) was first developed by Spielberg and colleagues in 
the 1980s to investigate patient susceptibility to DHS [14-17]. The test is based on the 
concept that DHS develops as a result of imbalance between activation (toxication) and 
detoxication of drugs in vivo (the reactive metabolite hypothesis).
[18]
 This hypothesis has 
provided partial explanations on how some patients are „genetically‟ predisposed to 
develop such reactions and others are not. Genetic polymorphism in enzymes involved in 
both activation and detoxifications of drugs has been demonstrated in DHS patients and 
healthy controls.
[19-21]
 The test includes isolation of peripheral blood lymphocytes 
(peripheral blood monocytes, PBMCs) from blood samples from patients and healthy 
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controls and incubation of these lymphocytes with the culprit drug for 2 hours at 37°C in 
presence of metabolic activation system (e.g., rat liver microsomes) in suitable media. 
After overnight recovery period at 37°C cell viability is then measured using different 
methods (Trypan blue exclusion method or MTT[3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] method).
[14, 22]
 It has been demonstrated that cells from 
hypersensitive patients are more susceptible to cell death induced by incubation with the 
culprit drug than cells from healthy controls. This observation has found a clinical 
application for the diagnosis of DHS and identifying the culprit agent usually among a 
group of suspected drugs.
[17, 23, 24]
 
The main obstacle that hinders accurate determination of predictive values of this 
test is lack of a safe gold standard test to measure it against. As a result, presently there is 
very little clinical data to confirm the LTA after re-exposure.
[10]
 In an attempt to close 
this gap we performed this cohort study on a group of patients who had been tested using 
the LTA for susceptibility to DHS. We aimed at identifying individuals who might have 
deliberately or inadvertently been exposed to the culprit drug(s) after having been tested. 
Our objective was to use these cases of re-exposure to calculate the negative and positive 
predictive value of the test.  
4.2. Methods 
4.2.1. Patient recruitment and data collection 
One hundred and forty seven patients were included in the study. These patients 
had developed hypersensitivity reactions to different drugs and were tested using LTA 
between 1991 to 2008 in two Drug Safety Clinics [Sunnybrook Health Sciences Centre 
(SHSC), Toronto, ON and the Children Hospital of Western Ontario (CHWO), London, 
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ON, Canada]. The drugs assessed included aromatic anticonvulsants (phenytoin, 
carbamazepine, phenobarbitone, lamotrigine), valproic acid, sulfonamides 
(sulfamethoxazole, sulfasalazine and sulfapyrazine), β-lactam antibiotics (amoxicillin, 
and cefaclor), macrolide antibiotics (erythromycin and clarithromycin), tetracycline, 
codeine and accutane. Subjects were identified from their medical records at the two 
locations. The inclusion criteria were: (1) the patient developed DHS as evaluated by the 
clinic specialist; (2) the patient was tested for susceptibility to DHS using the LTA; and 
(3) consent was obtained from the patient or parent (in case of children) to participate in 
the study. Patients were excluded from the study if their files did not contain sufficient 
information (contacts or LTA results) or they did not consent. 
Ethical approval was obtained from the Research Ethics Boards of SHCS and the 
University of Western Ontario and information letters were sent to each potential 
participant prior to contacting them. Verbal consents were obtained from participants or 
their parent (in cases of children patients) prior to inclusion in the study. 
4.2.2. Preparation of rat liver microsomes 
Adult Sprague Dawley rats (mean weight 200 g) were sacrificed by decapitation 
and their livers were quickly isolated under aseptic condition and washed with ice cold 
0.5 M potassium phosphate homogenization buffer. Livers were then diced with scissors 
and homogenized in 3 volumes homogenization buffer using drill powered Potter-
Elvehjem homogenizer. Homogenate were then centrifuged at 9000 g for 30 min at 4°C. 
Supernatants were then centrifuged at 100,000 g for 1 hr at 4°C. The pellets were then 
resuspended in homogenization buffer and stored at -80°C until used. Microsomal protein 
contents were determined by the method of Lowry et al.
[25]
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4.2.3. Blood collection and isolation of PBMCs 
Blood samples from patients and healthy volunteers were obtained by 
venepuncture, collected into heparinized syringes and separated immediately. To isolate 
lymphocytes samples were diluted 1:1 with phosphate buffered saline (NaCl, 137 mM; 
KCl, 2.7 mM; NaH2PO4, 10 mM; KH2PO4, 2 mM; pH of 7.4) and layered on a Ficoll
®
 -
paque density gradient. Gradients were then spun at 500 g for 20 minutes, the aqueous-
Ficoll interface layer was collected, washed twice with PBS and cell density was adjusted 
to 1×10
6
 cell per ml in 4-(2-hydroxymethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffered saline (HEPES, 15 mM; NaCl, 125 mM; KCl, 6 mM; MgSO4, 1.2 mM; 
NaHCO3, 1.0 mM; CaCl2, 1.0 mM; glucose, 10 mM;pH 7.4). At this stage cell viability is 
determined using trypan blue exclusion method and is always greater than 95%. All steps 
are performed in an aseptic condition in a laminar flow hood.  
4.2.4. The lymphocyte toxicity assay (LTA) 
The LTA was performed as previously described.
[14]
 Briefly, 100 µl of peripheral 
blood monocytes (PBMCs, lymphocytes) suspension at density of 1×10
6
 cell/ml were 
placed in each well of 96-flat-bottom multiwell plates. Cells were incubated with the 
either the drug (at concentrations ranged between 6.5 to 500 μM, aromatic 
anticonvulsants; beta-lactam antibiotics) or its reactive metabolite (In sulfa cases at 
concentration range 50 to 800 μM) for 2 hrs in humidified atmosphere at 37°C and 5% 
CO2 partial pressure. In experiments where the parent drug is used the metabolic 
activation system (rat liver microsomes, prepared as described above) was included in the 
incubation media. Microsomal protein was added at concentration of 0.25 mg/ml 
followed by addition of the NADPH generating system (NADP, 0.6 mM; glucose-6-
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phosphate, 2.4 mM; glucose-6-phosphate dehydrogenase, 2 U/ml). Plates were then spun 
down at 500 g for 15 minutes and media were replaced with fresh RPMI 1640 media 
containing 10% FBS and penicillin/streptomycine cocktail. Cells were then let to recover 
for 18 hrs in humidified atmosphere at 37°C and 5% CO2 partial pressure. At this point 
plates were spun down and resuspended in 100 µl HEPES buffer. 25µl of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at 5 mg/ml were added 
each well and incubated at 37°C for 4 hrs and reactions were stopped by adding 100 µl 
stop solution (NN-dimethylformamide, DMF, 50%; sodium dodecyl sulphate, SDS, 20%) 
and allowed to set overnight at room temperature, protected from light. The absorbance 
was measured at 590 nm by a Molecular Device Spectrophotometer (Beckman, Palo 
Alto, CA, USA). A standard curve as generated by seeding the cells at 0, 25, 50, 75 and 
100% of cell concentration in the corresponding buffer in quadruplicates. The data were 
analyzed using the Softmax
TM
 Molecular Device Group Analytical software version 2.35 
and statistical graphs were created using Microsoft Excel
TM 
2007 software. A cut-off 
value of 15% increase in cell death over base line (control) was used to determine 
positive tests. Patients were tested either in the lab of MJ Rieder at the University of 
Western Ontario or in the Drug Safety Clinic at Sunnybrook Health Sciences Centre. 
4.2.5. Follow-up interviews 
Information obtained from patient medical charts included patient age, gender, 
drugs tested, signs and symptoms of the reaction and LTA results. Participants were then 
asked to answer a standard questionnaire through telephone interviews. The questionnaire 
was designed to identify if the patient was exposed to the drug after being tested using the 
LTA and to find out the clinical response to the re-exposure. Patients were also asked 
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whether they have had allergic reactions to any other drugs or any family history of such 
reactions. The data obtained was analyzed to estimate  the test predictive values in the 
diagnosis of DHS.  
4.3. Results 
One hundred forty seven patients ranging between 3 and 89 years of age (mean 
30.1 year) consisted of 81 (55.1%) female and 66 (44.9 %) male were recruited. The LTA 
was performed on these patients as following: for AACs (n=124), for sulfa drugs (n=72), 
for β-lactam antibiotics (n= 76),  for macrolide antibiotics (n=10), for ciprofloxacin 
(n=3), for valproic acid (n=3),  for accutane (n=2), and 1for tetracycline and codeine. The 
LTA results were found to be negative in 179 tests (61.3%) and positive in 113 tests 
(38.7%). The majority of patients avoided any use of the suspected drugs after the first 
incidence regardless of the LTA test result. A subgroup of 22 patients had been exposed 
to a tested drug out of 147 patients studied (15.0%). In total of 26 events of re-exposure 
21 took place after a negative LTA and 5 after a positive LTA (Table 1). 
The clinical data collected at the first incidences vary among patients, including 
skin rashes (erythmatous or blistering), fever, edema, GIT, hepatitis, lung diseases, 
lymphadenopathy and hematological abnormalities (Table 2).  
Among the 26 cases of re-exposures in 22 patients 4 were true positive, 17 were 
true negative, 1 was false positive, and 4 were false negative as determined by syatemic 
re-exposure . Based on the limited number of re-exposure obtained the negative 
predictive value (NPV) of the LTA in the diagnosis of DHS vary according to the drug 
tested.  Among 13 cases of re-exposure to β-lactam antibiotics 2 were true positives, 8 
were true negatives and 3 were false negatives. This suggests low sensitivity and high 
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specificity of the test in diagnosis of DHS due to these drugs. On the other hand, 
sensitivity of the LTA in the diagnosis of DHS due to sulfonamides may be higher as no 
false negative results were identified among the 7 cases of re-exposure. Five re-exposures 
to aromatic anticonvulsants revealed 4 true negatives and 1 false negative. The overall 
sensitivity and specificity of the LTA in the diagnosis of DHS based on our 22 cases are 
estimated to be 40% and 90%, respectively. 
4.4. Discussion 
Drug hypersensitivity syndrome (DHS) is a rare disorder with high rates of morbidity and 
mortality. It represents a challenging clinical problem and increases patient care cost. 
While early diagnosis of DHS is essential for patient safety, that is not always achievable 
due to lack of a safe and reliable diagnostic tests. The LTA has been a promising 
diagnostic tool for such reactions but its clinical value has not been determined. To our 
knowledge this is the first study to use a „gold standard‟ test (systemic re-exposure) to 
validate the LTA. All previous attempts were based on correlation of suspected clinical 
manifestations and history of exposure with the LTA test. Clinical manifestations of DHS 
are quite variable and it is often difficult to associate a typical clinical picture to this 
disease.
[26]
 Furthermore, temporal relationship between administration of the suspected 
drug and development of the disorder is known to be of poor predictive value especially 
in cases where multiple drugs are used.
[14] 
 Previous studies have attempted to measure the diagnostic value of the test. 
Naranjo et al. (1994) evaluated the performance of LTA in diagnosis of drug 
hypersensitivity reactions using a Bayesian statistical instrument to determine causality 
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Table (1):  Characteristics of patients with drug hypersensitivity syndrome (DHS). 
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Characteristics Value 
Sex (female/male;n[%] 81/66 [55/45] 
Age (mean;y[range]) 30.1 [3-89] 
Type of reaction 
Skin rash only 
Systemic involvement 
None a 
 
45 [31] 
83 [56] 
19 [13] 
Drug tested b 
Sulfonamides 
Β-lactam antibiotics 
Aromatic anticonvulsants 
Others 
 
72 [25] 
76 [26] 
124 [43] 
20 [7] 
a: These are either relatives to patients or their clinical data are unavailable. 
b: patients may be tested for more than one drug. 
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Table (2): Characteristics of systemically re-exposed patients, their lymphocyte toxicity 
assay (LTA) results and results of re-exposure. 
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Patient 
no. 
Age 
(y) 
Sex Drug  tested 
LTA 
result 
Re-exposure 
1 15 male Amoxicillin - + 
2 9 male Amoxicillin - + 
3 12 Female Sulfamethoxazole -  - 
4 18 Female Sulfamethoxazole -  - 
5 66 Female Sulfamethoxazole - - 
6 63 Female Amoxicillin - - 
7 23 Female Cefaclor + + 
8 62 Female Sulfamethoxazole + + 
9 10 Female Amoxicillin - - 
10 25 male Sulfamethoxazole + - 
   Sulfamethoxazole - - 
11 17 male Cefaclor - - 
12 17 male Cefaclor - - 
13 13 Female Amoxicillin - - 
14 22 male Accutane + + 
15 9 male Cefaclor + + 
16 12 male Amoxicillin - + 
17 52 Female Phenobarbital - - 
18 14 male Phenytoin - - 
19 82 Female Carbamazepine - - 
20 14 male Phenobarbital - + 
   Lamotrigine - - 
21 8 Female Amoxicillin - - 
22 11 Female Sulfamethoxazole - - 
   Cefaclor - - 
   Amoxicillin - - 
+ indicates a positive test result; - indicates a negative test result 
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on 51 patients with suspected drug reactions. They estimated that LTA has a specificity 
of 75% and sensitivity of 99% in their studied cases. However, their study still lacked a 
„gold standard‟ measure such as systemic rechallenge.[27] In another study to validate the 
LTA in diagnosis of DHS Neuman et al. (2000) studied 86 patients with suspected 
reactions to sulfamethoxazole (SMX), 62 to anticonvulsants and 26 healthy volunteers. 
They estimated the negative predictive value of the test to be 64% and the positive 
predictive value to be 90% with sensitivity and specificity of 98% and 89%, 
respectively.
[22]
 However, no re-exposure data were available. In cases due to 
sulfonamides we found that the test has high NPV. This is possibly due in part to the 
simplified procedure to test for SMX which does not include in vitro metabolic 
activation. The toxic metabolite of sulfa drugs has been identified and synthesized and 
was found to be adequately stable to be used experimentally for the in vitro testing.
[28]
 
This step has provided a more simplified and apparently more sensitive test. The PPV of 
LTA in highly suspected cases of DHS due to SMX has been estimated previously to be 
between 80% and 90% [29, 30]. However, in these studies the parent drug not the 
metabolite was used in the in vitro toxicity testing. In our study, for drugs such as β-
lactam antibiotics (e.g., amoxicillin and cefaclor) however, the NPV was low which may 
be explained by the more complicated pathophysiology of hapten-mediated reactions 
caused by these drugs
.[31]
 Previous studies have suggested that the performance of LTA in 
cases of hypersensitivity to cefaclor depends largely on the type of reaction.
[32]
 Due to the 
retrospective nature of our study it was not possible to re-evaluate the patients clinically 
or to classify them according to the type of reaction. Having included cases in our study 
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with mixed types of reaction could be the cause for the relatively low NPV of LTA in β-
lactam antibiotics cases. 
The low sensitivity of the LTA test in β-lactam antibiotic cases is probably due to 
the complicated procedure of the test when using the metabolic activation system for 
drugs that need to be metabolized to a reactive (cytotoxic) metabolite(s). This is further 
supported by the good sensitivity of the test among SMX-induced cases.  
Considering the lack of complete understanding of the pathophysiology 
underlying DHS, it is difficult to speculate on how patient cells would react with the 
suspected drug in vitro. Drugs such as β-lactam antibiotics are known to cause different 
types of reactions and they are classical hapten forming agents.
[33]
 Different molecular 
mechanisms and requirements are thought to underlie each type of these reactions (i.e., 
Cell-mediated vs IgE-mediated) and some of them may not be detectable by the in vitro 
LTA test.
[6]
 Furthermore, the variable clinical picture of the DHS may lead to difficulty in 
identifying affected patients. Among our cases 30.6% developed type of skin rash only 
and 56.5% developed other systemic signs that included fever, hepatitis, respiratory 
diseases, hematological abnormalities, gastroenteritis, facial edema, anaphylaxis, 
angioedema, lymphadenopathy and serum sickness-like reactions.  
It is well established that 50% of all drugs in common use may cause some type 
of skin rash and that, in addition to fixed drug eruption, exanthematous (morbilliform, 
maculopapular or scarlatiniform) and urticarial rashes are the more common cutaneous 
adverse reaction.
[34]
 Exanthematous and pustular eruptions are more commonly 
associated with DHS as oppose to urticarial rash, which is usually caused by immediate 
type (type I) hypersensitivity reactions. The pathophysiological mechanisms of both 
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types of reactions are thought to be different.
[6]
 Taken together, one may expect that the 
LTA can have different predictive value in cases of both types of reactions; however, 
positive LTA tests were observed in this cohort in cases with all spectrums of cutaneous 
reactions (data not shown). This test detects the vulnerability of patient cells to the drug‟s 
reactive metabolite(s). According to the reactive metabolite hypothesis, drug activation is 
a pre-requisite for DHS to develop and this could be a common step in the cascade of 
events that lead to the development of different type of reactions. This is one of the LTA 
potential advantages; it detects the genetic susceptibility of the patient to develop DHS, 
thus the test can be also used for patient screening prior to prescribing a potential 
causative drug in high-risk populations. 
Although the number of re-exposed cases was relatively low to allow comparative 
statistics, our data provided a fair evaluation of the test performance in the diagnosis of 
DHS based on the definite power of systemic re-exposure. There is no doubt that better 
controlled prospective studies using more defined inclusion criteria are required to decide 
on the true clinical value of this test; however, there are several technical and ethical 
obstacles that should be overcome before such studies can be conducted.  
We have demonstrated anther critical aspect of the LTA that deserve discussion. 
From our data, it is evident that in most cases (88.3%) patients avoided reusing the 
suspected drug (as probably per their doctors‟ advices) despite reassuring negative 
results. This finding strongly suggests a situation of „mistrust‟ of the clinical value of the 
test which is a direct result of the lack of evidence-based data on its predictive value. It is 
unlikely that a diagnostic test with unknown predictive value will contribute to a better 
clinical practice.  
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The LTA can be a valuable diagnostic tool for patient susceptibility to DHS. 
Although the currently used procedure is quite complex and requires specialized 
experience. Further research may yield a more simplified test that is adaptable for wide 
clinical use. Such research is driven by the urgent need for a safe and reliable diagnostic 
test for DHS.  
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Chapter 5. The In vitro Platelet Toxicity Assay (iPTA): a Novel Approach for 
Assessment of Drug Hypersensitivity Syndrome. 
This chapter has been published previously: 
Elzagallaai AA, Rieder MJ, Koren G. The in vitro platelet toxicity assay (iPTA): a novel 
approach for assessment of drug hypersensitivity syndrome. J Clin Pharmacol. 2011 
Mar;51(3):428-35. 
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5.1. INTRODUCTION 
Adverse drug reactions (ADRs) account for 5% of all hospital admissions and 
occur in 10-20% of hospitalized patients.
1,2
 Most ADRs (85-90%) are predictable, dose-
dependent and related to the pharmacological action of the drug (type A), but 10-15% are 
unpredictable, unrelated to the pharmacological action of the drug and do not have clear 
dose dependency (type B).
3,4
 A major category of the latter type is Drug Hypersensitivity 
Syndrome (DHS).
5,6
 DHS is a rare but potentially fatal disorder that occurs in susceptible 
patients following exposure to the culprit drug. It is most commonly associated with 
aromatic anticonvulsants (e.g., phenytoin, carbamazepine, phenobarbital and lamotrigine) 
and antimicrobials such as sulfonamides.
5-7
  
It has been difficult to establish a diagnosis of DHS due to its variable clinical 
presentation, overlap with other clinical conditions and the often delayed temporal 
relationship between administration of the culprit drug and the appearance of symptoms.
8
 
Lack of a reliable and safe diagnostic test plays a major role in the significant morbidity 
and mortality due to drug hypersensitivity.
9,10
 Other than systemic re-challenge with the 
culprit drug, no gold standard diagnostic test is currently available. Unfortunately, 
systemic re-challenge is ethically problematic.
11
 Currently available in vivo and in vitro 
tests are not well characterized and their sensitivity and specificity are unknown.
12,13
 
Attempts to develop safe and reliable in vitro diagnostic tests for DHS have been 
underway for decades; however, recent systematic reviews of both in vivo and in vitro 
diagnostic tests for DHS have documented a paucity of large scale studies to evaluate the 
usefulness of these tests.
14,15
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The lymphocyte toxicity assay (LTA) is an in vitro diagnostic test that was 
developed three decades ago to investigate patient susceptibility to drug 
hypersensitivity.
16,17
 The usefulness of this test in diagnosing DHS is yet to be 
determined as its negative and positive predictive values are still unclear.
14
 The main 
disadvantage of this test is the lengthy and complicated method used to isolate peripheral 
blood lymphocytes. This involves centrifugation of diluted blood samples over a gradient 
of synthetic high molecular weight polymer of sucrose (Ficoll
®
) and isolation of a narrow 
layer that contains lymphocytes, monocytes and a high number of attached and co-
sedimented platelets.
18,19
 This lengthy process complicates the assay, increases its cost 
and may contribute to its poor reproducibility.  
In an attempt to simplify and improve the LTA procedure, we have explored the 
possibility to use another blood cell type as a surrogate cell model for the test. We 
hypothesized that platelets would be a suitable candidate for this role. Platelets are 
metabolically active non-nucleated cells derived from the cytoplasm of polyploid 
megakaryocytes. They are 2.0 to 5.0 µm in diameter and 0.5 µm in thickness and 
circulate in a density of 150-450×10
9
 cell/liter in healthy individuals
20
 Because of their 
small size and low density, platelets are very easy to obtain from peripheral blood 
samples using simple differential centrifugation methods
21,22
 In addition to their well 
known pivotal role in blood homeostasis and thrombosis, a great deal of evidence has 
recently emerged on the role of platelets in inflammation, allergy and hypersensitivity 
reactions, as well as having effects on immunity
23-26
 Platelets contain active mitochondria 
and have a complete machinery for apoptosis which suggests that they may be a good 
model to study cell toxicity.
27-29
 Furthermore, being unable to proliferate, platelets 
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provide an extra advantage in accurately reflecting the degree of cell death upon exposure 
to chemical insult, an effect that can be masked by cell replication in other proliferating 
cell types (e.g. lymphocytes). 
The present work is the first report on the use of blood platelets as surrogate cells 
for in vitro toxicity testing of drugs. Data described here suggest that using platelets as 
target cells may be a novel technique to predict the susceptibility of patients to develop 
drug hypersensitivity. 
5.2. MATERIALS AND METHODS 
5.2.1. Chemicals 
  The hydroxylamine metabolite of sulfamethoxazole (SMX) was synthesized as 
described previously,
30
 and determined by HPLC, mass spectrometry, and nuclear 
magnetic resonance to be >99% pure. Carbamazepine, sulfamethoxazole, glucose-6-
phosphate, β-nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt 
(NADP),  glucose-6-phosphate dehydrogenase (type XV from bakers yeast) and the 
tetrazolium salt 3-(4, 5-dimethylthiazol-2-yl) 2, 5 diohenyl-tetrazolium bromide (MTT) 
were purchased from Sigma-Aldrich Canada, Ltd. (Oakville, Ontario, Canada). All 
remaining reagents were of analytical grade obtained from the usual commercial sources. 
Drugs were prepared as stock solutions in dimethyl sulfoxide (DMSO) and diluted in the 
used buffer to obtain the desired working concentrations. The final concentration of 
DMSO in the media was always less than 0.2 %. 
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5.2.2. Patients 
Patients were selected according to the following criteria: 1) having a medical and 
clinical history highly suggestive of DHS due to carbamazepine (CBZ) or 
sulfamethoxazole (SMX) and/or 2) patients that had a positive LTA test to CBZ or SMX. 
Blood samples were obtained from 8 individuals: two patients who had developed 
hypersensitivity reactions (DHR) to drugs as suggested by medical history and clinical 
manifestations; two patients who had never been exposed to the culprit drugs but were 
diagnosed to be susceptible to DHR by the conventional LTA; and four healthy 
volunteers who have denied any history of hypersensitivity reaction to the drugs or prior 
exposure to the drugs. The patient group consisted of 3 adults (mean age 42.3 years) and 
a child (9 years) who denied having been on any drug other than the suspected agent. The 
study was approved by the University of Western Ontario research ethics board and 
consent was obtained from participants or their guardians. 
5.2.3. Blood collection and cells isolation  
Blood samples from the patients and healthy volunteers were obtained by 
venipuncture, collected into heparinized syringes and separated immediately. To isolate 
lymphocytes, samples were diluted 1:1 with phosphate buffered saline (NaCl, 137 mM; 
KCl, 2.7 mM; NaH2PO4, 10 mM; KH2PO4, 2 mM; pH of 7.4) and layered on a Ficoll
®
-
paque density gradient. Gradients were then spun at 500 x g for 20 minutes, the aqueous-
Ficoll interface layer was collected, washed twice with PBS and cell density was adjusted 
to 1×10
6
 cell/ml in 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) 
buffered saline (HEPES, 15 mM; NaCl, 125 mM; KCl, 6 mM; MgSO4, 1.2 mM; 
NaHCO3, 1.0 mM; CaCl2, 1.0 mM; glucose, 10 mM; pH 7.4). At this stage cell viability 
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is determined using trypan blue exclusion method and is always greater than 95%. All 
steps are performed in an aseptic condition in a laminar flow hood.  
To collect platelets, blood samples were centrifuged at 200 x g for 15 minutes and 
the platelet rich plasma was then centrifuged at 900 x g for 15 minutes to pellet platelets. 
Platelets were then washed twice with modified calcium-free Locke‟s solution (NaCl, 
154 mM; KCl, 2.6 mM; K2HPO4, 2.14 mM; KH2PO4, 0.85 mM; MgCl2, 1.2 mM; 
glucose, 10 mM; and EGTA, 2.0 mM; pH 7.2)  supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) and cell density was adjusted to 7.5 × 10
8 
cell/ml in calcium-
free Locke‟s solution.  
5.2.4. Preparation of rat liver microsomes (RLM)  
Adult Sprague Dawley rats (mean weight 200 g) were sacrificed by decapitation 
and their livers were quickly isolated under aseptic condition and washed with ice cold 
0.5 M potassium phosphate homogenization buffer (pH 7.2). Livers were then diced with 
scissors and homogenized in 3 volumes homogenization buffer using drill powered 
Potter-Elvehjem homogenizer. Homogenate were then centrifuged at 9000 x g for 30 min 
at 4°C. Supernatants were then centrifuged at 100,000 x g for 1 hr at 4°C. The pellets 
were then resuspended in homogenization buffer and stored at -80°C until used. 
Microsomal protein contents were determined by the method of Lowry et al. (1951).
31
 
5.2.5. The in vitro toxicity assay 
 The conventional LTA was performed as described previously.
6
 Briefly, 100 µl of 
peripheral blood monocytes (PBMCs, lymphocytes) suspension at density of 1×10
6
 
cell/ml were placed in each well of 96-flat-bottom multiwell plates. Cells were incubated 
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with either the drug in question or its reactive metabolite for 2 hrs in humidified 
atmosphere at 37°C and 5% CO2 partial pressure. In experiments where the parent drug 
was used, the metabolic activation system was included in the incubation media. 
Microsomal protein was added at a concentration of 0.25 mg/ml followed by the NADPH 
generating system (NADP, 0.6 mM; glucose-6-phosphate, 2.4 mM; glucose-6-phosphate 
dehydrogenase, 2 U/ml). Plates were then spun down at 500 x g for 15 minutes and media 
were replaced with fresh Roswell Park Memorial Institute (RPMI) 1640 media containing 
10% FBS and penicillin/streptomycine cocktail. Cells were then let to recover for 18 hrs 
in humidified atmosphere at 37°C and 5% CO2 partial pressure. At this point plates were 
spun down and resuspended in 100 µl HEPES buffer. 25µl of MTT at 5 mg/ml were 
added to each well and incubated at 37°C for 4 hrs and reactions were stopped by adding 
100 µl stop solution (N,N-dimethylformamide, DMF, 50%; sodium dodecyl sulphate, 
SDS, 20% in DDH2O) and allowed to set overnight at room temperature protected from 
light. Absorbance was measured at 590 nm by a Molecular Devices spectrophotometer 
(Beckman, Palo Alto, CA, USA). A standard curve was generated by seeding cells at 0, 
25, 50, 75 and 100% of concentration in the corresponding buffer in quadruplicates. The 
data were analyzed using the Softmax
TM
 Molecular Devices Group Analytical software 
version 2.35 and graphs were created using Microsoft Excel
TM 
2007 software. 
 The in vitro platelet toxicity assay (iPTA) was performed in a similar procedure 
except that calcium-free Locke‟s solution was used as a medium in the experiments. 
Platelets were incubated at density of 7.5×10
8
 platelets/ml and plates were centrifuged at 
900 x g in each step to pellet platelets. 
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5.2.6. Microscopic examination of the platelet preparation 
 Samples from isolated platelets were spun onto glass slides using a bench-top 
cytospin centrifuge, fixed in absolute methanol for 30 minutes and stained with Wright-
Giemsa stain for 20 minutes. They were then washed several times with distilled water, 
mounted and visualized by phase-contrast under Olympus light microscope using oil 
immerged objective (100X, 1.3 aperture). 
5.2.7. Statistical analysis of data 
 Data were analyzed using Microsoft Excel
TM
 2007 software and differences between 
patients and controls were determined by t-test with Bonferroni correction for multiple 
comparisons. Values are expressed as percentage of control (vehicle only) and presented 
as mean ± standard error (SE). 
5.3. RESULTS 
5.3.1. Determination of platelets viability using MTT method 
  These experiments were carried out to determine whether cell death can be used as a 
measurable in vitro end point for platelet susceptibility to reactive metabolites. Platelets 
isolated from blood samples drawn from normal volunteers were incubated with different 
concentrations (50, 100 and 200 µM) of sulfamethoxazole hydroxyl amine (SMX-HA, 
the cytotoxic metabolite of SMX) for 2 hrs at 37°C and 5% CO2. At the same time 
PBMCs isolated from the same samples were incubated under identical conditions side 
by side. After incubation, media were replaced with fresh RPMI 1640 media and allowed 
to recover for 18 hrs. The viability of both platelets and PBMCs was then determined 
using MTT as described above. SMX-HA induces concentration-dependent cell death in 
platelets in vitro in a similar manner as in PBMCs (figure 1). However, the cytotoxic 
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metabolite induced more cell death in platelets at 100 and 200 μM (percentage: 18.9±4.5 
and 44.5±6.6; respectively, n=12) than in PBMCs (percentage: 5.4±4.3 and 16.7±3.9; 
respectively, n=12) (p<0.05). Platelets were able to convert the yellow tetrazolium to a 
spectrophotometrically measurable blue formazan. Conversion of the tetrazolium to the 
formazan depends on the activity of the mitochondrial succinyl dehyrogenase enzyme 
indicating viability.
32
   
 To rule out the possibility that our platelet preparations may be contaminated with 
other types of blood cells (e.g., erythrocytes), we performed microscopic examination of 
samples from the isolated platelets. Slides from samples taken from platelet preparations 
were prepared as described above and examined under a light microscope. At least 
99.95% of cells observed were platelets confirmed by the characteristic morphology of 
platelets (figure 1, insert).  
5.3.2. Comparison of induction of cell death between PBMCs and platelets from 
hypersensitive patients and healthy controls  
 We isolated PBMCs and platelets from 2 patients who had been diagnosed as 
susceptible to developing hypersensitivity reaction to SMX using the LTA. In parallel 
blood samples were withdrawn from 2 healthy volunteers with no history of exposure or 
hypersensitivity reaction to SMX. Platelets and PBMCs from both groups were incubated 
with increasing concentrations of SMX-HA (0-400 µM) and cell viability was then 
measured using the MTT method as described above.
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Figure (1) Peripheral blood monocytes (PBMCs) (empty circles) and platelets (solid 
circles) from healthy volunteers were isolated and incubated with increasing 
concentrations of sulfamethoxazole hydroxylamine (SMX-HA). Cell death was then 
determined using the MTT method and expressed as percentage of control (vehicle 
without drug). Values are presented as mean±S.E. of at least 12 replications. Insert: 
Samples from platelets preparations were spun onto glass slides, fixed, stained with 
Wright-Giemsa stain and visualized under Olympus light microscope equipped with 
100X objective lens (1.3 aperture). The figure shows a representative picture. Arrows 
indicate small platelet aggregates.*, p<0.05. 
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Figure (2) PBMCs (A) and platelets (B) from a healthy control (white bars) and from 
SMX-hypersensitive patient (shaded bars) were isolated and incubated with increasing 
concentrations of SMX-HA and cell death was then determined using the MTT method 
and expressed as a percentage of control (vehicle without drug). C: Platelets from a 
healthy control (white bars) and from a clinically suspected SMX-hypersensitive patient 
(shaded bars) were isolated and incubated with increasing concentration of SMX-HA or 
800 µM SMX and cell death was then determined using MTT method and expressed as 
percentages of control (vehicle without drug). D: Platelets from a healthy control and a 
clinically suspected CBZ-hypersensitive patient were isolated and incubated with either 0 
µM or 250 µM CBZ in presence or absence of rat liver microsomes (RLM). Values are 
presented as mean±S.E. of at least 6 repitations from each subject. PBMCs, peripheral 
blood monocytes; SMX, sulfamethoxazole; SMX-HA, sulfamethoxazole hydroxylamine; 
CBZ, carbamazepine; RLM, rat liver microsomes. *, p<0.05. 
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 As anticipated, incubation of PBMCs from a patient with SMX hypersensitivity 
induced a concentration-dependent increase in cell death higher than in PBMCs isolated 
from a healthy volunteer which was statistically significant at all concentrations tested 
(p<0.05) (figure 2A). At 400 µM SMX-HA, for instance, the percentage of cell death was 
29.1±1.0 (n=12) in PBMCs from a healthy volunteer vs. 67.6±1.2 in PBMCs isolated 
from an SMX hypersensitive patient with a difference of around 38.5% (p<0.05). When 
platelets isolated from the same hypersensitivity patient and healthy volunteer were 
incubated with increasing concentrations of SMX-HA (0-400 µM) the difference in 
induction of cell death was higher and significant at all concentrations tested (p<0.05) 
(figure 2B). As a comparison to PBMCs the percentage of induction of cell death at 400 
μM SMX-HA in platelets from the patients was 94.4±5.2 (n=12) and in platelets from the 
healthy volunteer was 42.9±1.1 (n=12) with a difference of around 51.5%, suggesting 
that the platelet test is more sensitive than the conventional LTA.   
5.3.3. Response of platelets from a clinically suspected hypersensitive patient  
 Blood samples were taken from a 58-year old woman who had developed high fever 
after taking a course of Septra
TM
 (sulfamethoxazole/trimethoprim) in the past and from 
one healthy volunteer with no sulfonamide exposure. Platelets from the SMX 
hypersensitive patient exhibited more cell death than platelets from the healthy volunteer 
(figure 2 C) (p<0.05, with 6 samples from each). In fact, at 400 µM SMX-HA almost 
100% cell death was observed in platelets from the hypersensitive patient (figure 2 C). In 
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contrast, incubation of platelets from the patient and control with up to 800 µM SMX (the 
parent drug) did not induce a significant amount of cell death (p = 0.4). 
5.3.4. Response of platelets from a carbamazepine (CBZ)-hypersensitive patient to 
RLM-generated toxic metabolite(s) of CBZ 
 Platelets from a patient who had clinical symptoms suggestive of hypersensitivity 
reaction after exposure to CBZ, and from one healthy volunteer, were incubated with 250 
µM CBZ in the presence (+RLM) and absence (-RLM) of rat liver microsomes and 
NADPH-generating system as described above. Each test was repeated on 6 samples to 
identify intra-test reproducibility. In the patient‟s platelets there was around 20% increase 
in cell death in the presence of microsomes and NADPH-generating system  compared to 
platelets from the healthy volunteer (cell viability: 84±3.9 and 106± 0.73; respectively, 
p<0.05, n=12) (Figure 2 D). Neither platelets from the healthy volunteer under both 
conditions (-RLM or +RLM) nor platelets from the patient incubated without microsomes 
(-RLM) shown any increase in cell death compared to control (vehicle without drug). 
5.4. Discussion 
 The pathophysiology underlying drug hypersensitivity is not well understood. 
However, several mechanistic frameworks have been introduced including the hapten 
hypothesis and the reactive metabolite hypothesis.
8,33
 The latter hypothesis assumes that 
drug hypersensitivity reactions develop as a result of imbalance between bioactivation 
and detoxification processes of drugs in the body. Mechanistic studies using in vitro 
cellular model have shown that certain phase I oxidation enzymes appear to be  
responsible for generation of toxic metabolites which can then induce cell death in 
vitro.
34
 It has been shown that PBMCs from hypersensitive patients and their family 
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members are more susceptible to cell death upon exposure to the culprit drug (or its 
metabolites) than cells from healthy subjects.
6,35
  
 A common property of most drugs implicated in eliciting DHS is their being 
extensively metabolized to more reactive and cytotoxic species, such as aromatic 
anticonvulsants (AACs) and sulfonamides.
36
 Although the culprit metabolite(s) of AACs 
is/are yet to be identified, many in vivo and in vitro investigations have suggested arene 
oxide derivatives of these aromatic compounds are the culprits.
37-39
 These species are 
chemically short lived, highly reactive and capable of modifying intracellular 
macromolecules (DNA, proteins) which can then act as haptens activating the immune 
system.
33
 A major obstacle in in vitro toxicity testing of AACs is the unavailability of 
these suspected “reactive” metabolites for quantification and study due to their instability. 
Using the metabolic activation system (liver microsomes) to generate these metabolites in 
vitro is a complicated process which presently lacks both standardization and 
reproducibility.
40
 The sulfonamide sulfamethoxazole (SMX) is metabolized in vivo to 
several primary and secondary metabolites including hydroxylamine (HA) derivative by 
cytochrome P 450 (CYP) 2C9 and myeloperoxidase (MPO) enzymes. This metabolite 
can undergo auto-oxidation to form the protein reactive nitroso species that is capable of 
covalently binding to cellular macromolecules, causing direct cell death and forming 
hapten complexes that can evoke immunological reactions.
41
 Rieder et al. (1988)
30
 
synthesized and used sulfamethoxazole hydroxylamine (SMX-HA) for in vitro 
rechallenge of lymphocytes from patients to determine their predisposition to 
hypersensitivity reactions to sulfonamides.  
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 Data presented here introduce and characterize for the first time an in vitro platelet 
toxicity assay (iPTA) which employs peripheral blood platelets as a surrogate model to 
test for patient susceptibility to DHS. The iPTA may have advantages and potential 
applications in clinical settings due to its low cost and simple procedure. Compared to 
PBMCs, we show that platelets from hypersensitive patients not only respond similarly, 
but the degree of cell death was greater and easier to detect than in PBMCs (figure 2 A 
and B). This observation can be explained by the fact that platelets do not proliferate as 
lymphocytes do, avoiding potential masking of cell death. In addition, platelets lack 
nuclei and capacity for protein synthesis that compromises their defense against reactive 
metabolite effects (e.g., glutathione S-transferase and glutathione contents can be easily 
exhausted).  
 We observed different degrees of cell death after exposure of platelets isolated from 
different individuals (figures 2 B and C). This can be attributed to difference in 
sensitivity of the target cells. Susceptibility of the cells to in vitro toxicity is probably not 
all-or-none but rather a graded response which is observed in testing different patients.
42
 
The question whether there is a certain threshold or level at which a reaction may develop 
is difficult to answer given that DHS involves several cascades of events leading to the 
clinical manifestations, and multiple mechanisms that may underlie the disease. A much 
larger study with more strictly defined clinical cases will be useful in answering this 
question. 
 A number of reports have recently documented a role for platelets in allergic 
inflammation, hypersensitivity reactions and modulation of leukocyte function.
23,25,43,44
 
 133 
 
 
This provides further support for the rational of using platelets as a model cell for in vitro 
testing of hypersensitivity reactions. Historically, Comaish (1968) tested patients with 
suspected drug allergy  using peripheral platelets and the increase in the release of radio-
labeled serotonin (5-HT) as an end-point.
45
 Abnormal cellular response was also 
observed after incubation of washed platelets from aspirin-sensitive asthma with NSAID 
drugs in vitro.
46
 
 In summary, our studies document for the first time that platelets react in a manner 
similar to PBMCs in response to AACs and sulfonamides. They are easy to obtain from 
small blood samples, and do not proliferate, which makes them ideal for cytotoxicity 
assays in vitro.  As well, they contain the full apoptotic machinery to explore molecular 
mechanisms of cell death. More research with larger groups of patients is needed to 
confirm our findings. The new assay was established by us in single cases of CBZ and 
SMX severe ADRs showing excellent intra-assay reproduciability and significant 
differences from controls. We are now collecting multiple cases to validate the assay in 
the near future for both drugs. 
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Chapter 6. Severe bullous hypersensitivity reactions after exposure to 
carbamazepine in a Han Chinese child with a positive HLA-B*1502 and a negative 
lymphocyte toxicity assay: Evidence for different pathophysiological mechanisms. 
 
This Chapter has been published previously: 
Elzagallaai AA, Garcia-Bournissen F, Finkelstein Y, Bend JR, Rieder MJ, Koren G. 
Severe bullous hypersensitivity reactions after exposure to carbamazepine in a Han-
Chinese child with a positive HLA-B*1502 and negative in vitro toxicity assays: 
evidence for different pathophysiological mechanisms.J Popul Ther Clin Pharmacol. 
2011;18(1):e1-9.  
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6.1. Introduction 
Drug hypersensitivity syndrome (DHS) or drug rash with eosinophilia and systemic 
symptoms (DRESS) is a life-threatening type of adverse drug reaction (ADR). It is 
unpredictable, unrelated to the drug‟s direct pharmacological action and does not have a 
clear dose-effect relationship. These features put DHS among type-B (bizarre) ADRs as 
opposed to Type-A (augmented) reactions, which are predictable from the 
pharmacological action of the drug, and are dose-dependent.
1
 DHS is defined as a 
constellation of symptoms that may include fever, skin rash and internal organ 
involvement following drug exposure.
2
 The true incidence of DHS is unknown; however, 
some authors have reported a rate as high as 13.5% of all ADRs.
3,4
 The lack of a clear 
clinical definition for this disorder and the absence of any safe, validated diagnostic test 
have limited the ability to confirm this type of ADR, and may have contributed to the 
significant morbidity and mortality related to delayed diagnosis. 
The clinical manifestations of DHS can be quite diverse, ranging from mild self-
resolved maculopapular eruptions to severe life-threatening cutaneous reactions involving 
multi-system dysfunction.
5
 The reactions may also take the form of a severe bullous skin 
eruption with systemic involvement (e.g., Stevens-Johnson syndrome, SJS and toxic 
epidermal necrolysis, TEN) with a mortality rate of up to 40%.
6
 The DHS spectrum has 
also been classified according to the type of skin reaction: bullous cutaneous ADRs 
(cADRs), which include SJS; and TEN and non-bullous cADRs, which include other 
types of reactions that comprise DHS. The diagnostic criteria of DHS have been a subject 
of lengthy debate, notably as to whether the severe forms of the disorder are variants of 
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the same syndrome or completely different pathological entities.
7,8
 The nomenclature of 
DHS is far from consensus; however, for the purpose of this study we have used „non-
bullous CBZ-DHS‟ to indicate carbamazepine-induced hypersensitivity syndrome that is 
not SJS or TEN. The latter are denoted as CBZ-SJS/TEN. 
The lymphocyte toxicity assay (LTA) is an in vitro diagnostic test that has been used 
for decades to investigate patient susceptibility to DHS.
9
 The test is based on the 
hypothetical framework that susceptible patients have diminished ability to detoxify 
reactive electrophilic metabolites of the culprit drugs (or more recently reactive 
electrophilic by-products formed during the metabolism of the drug such as the lipid 
peroxidation product, 4-hydroxynonenal); and thus, form them at amounts that can cause 
DHS (the reactive metabolite hypothesis), presumably by the development of misdirected 
immune response. The latter hypothesis has been applied to clinical cases for the 
diagnosis of DHS.
10,11
  
Several lines of evidence exist supporting the genetic basis of patient susceptibility 
to DHS. Familial occurrence of DHS has been documented with cells isolated from 
relatives of patients that are also susceptible to in vitro toxicity.
9,12
 Other evidence comes 
from the discovery of an association between the existence of certain HLA alleles and 
patients‟ susceptibility to DHS induced by drugs such as the anti HIV reverse-
transcriptase inhibitor, abacavir and the antiepileptic, carbamazepine (CBZ).
13,14
 These 
findings also strengthened the proposed immunological etiology of DHS as genetic loci 
within the major histocompatibility complex (MHC) region have been suggested to be 
involved. One of the strongest associations was found between the susceptibility to CBZ-
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induced SJS/TEN (CBZ-SJS/TEN) in Han Chinese patients and the occurrence of the 
HLA-B*1502 allele.
13,15
 This genetic variation has 100% sensitivity and 97% specificity 
for prediction of severe bullous reactions due to CBZ exposure in Han-Chinese 
populations. This discovery has prompted the US-FDA to issue a recommendation to test 
any patient with Asian ancestry for the HLA-B*1502 allele before initiating CBZ 
therapy.
16
 It appears, however, that having the HLA-B*1502 allele is predictive of only 
severe bullous reactions in the Southeast Asian population to CBZ.
17
 Of note, other 
studies have not found any association between this specific genetic marker and the 
disease in other ethnic groups.
18-20
  
To the best of our knowledge, the present study is the first to attempt to unravel the 
complexity of DHS pathogenesis using both genetic and biochemical evidence.  
6.2. MATERIALS AND METHODS 
6.2.1. Case Report 
An 11 year-old boy with epilepsy of Han-Chinese origin presented to our Emergency 
Department with SJS after receiving CBZ treatment for 2 weeks. He had previously been 
treated with phenobarbital (PHB) for more than a year. The ADR started with fever and rash 
that rapidly progressed to significant cutaneous and corneal involvement.  
Dermatological examination confirmed mucosal ulceration followed by 
maculopapular rash on the trunk, face and arms progressing to confluent macules 
covering more than 50% of the body with extensive bullae and erythematous vesicles on 
peripheries, and epidermolysis of 10% of body surface area, requiring skin debridement 
by a plastic surgeon. Ophthalmological examination revealed bilateral epithelial defects 
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and blurred vision. Blood haemoglobin content was 126 g/L, but dropped to 61 g/L on 
day 5 requiring transfusion (2 units of blood). C-reactive protein (CRP) content was 84.9 
mg/L. There was also mild elevation of liver enzymes in the plasma, (ALT, 325 U/L; 
Amylase, 389 U/L; AST, 375 U/L; LDH, 1941 U/L) and transient hyperglycemia. 
Serology showed negative IgM for CMV and Mycoplasma pneumonia. The boy was 
treated with IVIG 1g/kg/day for 3 days, corticosteroid eye drops, and surgical 
debridement of bullae. He recovered well and was discharged from hospital. The 
Research Ethics Boards of the University of Western Ontario and the Hospital for Sick 
Children approved this study. 
6.2.2. HLA Typing 
HLA-A, B, C and DR low resolution typing was performed using polymerase chain 
reaction-sequence-specific oligonucleotide (PCR-SSO) method and HLA-B*15 and 
Cw*08 high resolution typing was performed using polymerase chain reaction-sequence 
specific primer (PCR-SSP) method (Toronto Regional Histocompatibility Laboratory, 
Toronto, ON, Canada).  
6.2.3. In vitro Toxicity Testing 
The lymphocyte toxicity assay (LTA) was performed as described previously.
9
 Briefly, 
100 µl of a peripheral blood monocyte suspension (PBMCs, lymphocytes), at a density of 
1×10
6
 cell/ml, were placed in each well of 96-flat-bottom multiwell plates. Cells were 
incubated with different concentrations of CBZ for 2 hrs in a humidified atmosphere at 
37°C and 5% CO2 partial pressure. Microsomal protein (0.25 mg/ml) was added followed 
by an NADPH generating system (NADP, 0.6 mM; glucose-6-phosphate, 2.4 mM; 
glucose-6-phosphate dehydrogenase, 2 U/ml). Plates were then spun at 500 g for 15 min 
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and media was replaced with fresh RPMI 1640 media containing 10% FBS and 
penicillin/streptomycin cocktail. Cells were allowed to recover for 18 hrs in a humidified 
atmosphere at 37°C and 5% CO2 partial pressure. At this point, plates were spun down 
and contents resuspended in 100 µl HEPES buffer. An aliquot (25µl) of a 5 mg/ml 
aqueous solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was added to each well and incubated at 37°C for 4 hrs. Reactions were stopped 
by adding 100 µl stop solution (50% N, N-dimethylformamide, DMF; sodium dodecyl 
sulphate, SDS, 20%) and allowed to set overnight at room temperature, protected from 
light. The absorbance was measured at 590 nm by a Molecular Device 
Spectrophotometer (Beckman, Palo Alto, CA, USA). A standard curve was generated by 
seeding the cells at 0, 25, 50, 75 and 100% of cell concentration in the corresponding 
buffer in quadruplicate. The data were analyzed using the Softmax
TM
 Molecular Device 
Group Analytical software version 2.35 and statistical graphs were created using 
Microsoft Excel
TM 
2007 software. 
The in vitro platelet toxicity assay (iPTA) was performed in a similar procedure as above 
except, calcium-free Locke‟s solution was used as the medium in the experiments. 
Platelets were incubated at a density of 7.5×10
8
 cells/ml and plates were centrifuged at 
900 x g, in each step to pellet platelets. 
6.2.4. Statistical Analysis of Data 
 Data were analyzed using Microsoft Excel
TM
 2007 software and differences between 
cells from the patient and those from controls were determined by Student‟s t-test with 
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Bonferroni correction for multiple comparisons. Values are expressed as percentage of 
control (vehicle only) and presented as mean ± standard error (SE). 
6.3. RESULTS 
We performed the in vitro toxicity assays using cells from healthy volunteers and 
the patient 3 months and 9 months after his recovery from the reaction. The patient‟s cells 
(PBMCs, LTA and platelets, iPTA) did not show any significant increase in cell death 
upon incubation with up to 250μM CBZ in the presence of fortified rat liver microsomes 
(RLM) compared to healthy controls (Table 1). We performed an identical in vitro 
toxicity assay to cells of a Caucasian patient who had typical non-bullous DHS to CBZ 
(non-bullous CBZ-DHS). Cells from the non- bullous CBZ-DHS  
patient showed a significant increase in cell death (~20%) upon exposure to CBZ and its 
metabolites compared to cells from the healthy volunteer (p<0.05, n=12) (Table 1). 
Genotyping for HLA-A, B, C and DR and for HLA-B*15 and Cw*08 revealed that the 
CBZ-SJS Chinese patient carries the HLA-B*1502 allelle. 
6.5. DISCUSSION 
Aromatic anticonvulsants (AACs) are one of the drug classes most commonly associated 
with DHS.
21
 They include clinically important drugs such as Phenytoin (DPH), 
Carbamazepine (CBZ), Phenobarbital (PHB) and Lamotrigine (LMG). CBZ is the drug 
of choice as first line therapy for certain types of epileptic seizure, including partial 
seizures and tonic-clonic seizures. CBZ is also used to treat chronic pain and certain 
psychiatric disorders. Carbamazepine-induced DHS is characterized by variable clinical 
presentations and different degrees of severity. The condition can present as 
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TABLE  1  Results of in vitro toxicity testing of CBZ-SJS patient, CBZ-DHS patient and healthy 
controls 
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Time of the in vitro 
toxicity assay
a
 
Subject 
In vitro toxicity testing 
LTA iPTA 
3 months 
CBZ-SJS Patient NEG
b
 NEG 
Healthy control NEG NEG 
9 months 
CBZ-SJS patient NEG NEG 
Healthy control NEG NEG 
3 months 
CBZ-DHS patient POS POS 
Healthy control NEG NEG 
a: Time elapsed between the reaction and the test. b: To determine test result we used 20% 
increase in cell death as a cut-off value, see Method section for details; LTA- lymphocyte 
toxicity assay; iPTA- in vitro platelet toxicity assay; CBZ- carbamazepine; SJS- Stevens 
Johnson syndrome; DHS- drug hypersensitivity syndrome. 
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maculopapular skin rash that may be accompanied with fever and other systemic 
symptoms in virtually any organ. The disease can also develop as a severe bullous 
reaction that involves skin, mucosal membranes and ocular tissue (SJS and TEN). 
 Carbamazepine and its oxidative metabolites can activate T-cells from DHS 
patients in vitro
22,23
 and both CBZ and its major metabolite, CBZ-epoxide, yield a 
positive patch test in CBZ-hypersensitive patients.
24,25
 Carbamazepine-specific CD4
+
, 
CD8
+
 and CD4
+
/CD8
+
 T-cell clones have been generated in vitro from blood samples of 
CBZ-hypersensitive patients.
26
 In light of the currently available data, it may be naive to 
define CBZ-induced hypersensitivity reactions as a constellation of symptoms ranging 
from simple maculopapular skin rash with fever to severe bullous skin manifestation with 
multisystem dysfunction; as this definition does not address the distinct histopathological 
and immunological features of different forms of CBZ-induced hypersensitivity 
reactions. Additionally, genetics may play a major role in determining the susceptibility 
of patients to CBZ-induced hypersensitivity reactions, because of their familial and ethnic 
occurrence, as certain types of AACs-induced hypersensitivity reactions were found to 
run in families.
12,20,27
  
The search for genetic markers for ADRs has been underway for a long time and was 
accelerated by the recent improvement in quality and decreased cost of gene analysis 
methods. Because it was known that metabolic bioactivation plays an essential role in the 
development of some hypersensitivity reactions, the first candidates were genes that 
control the main metabolic enzymes (e.g., cytochrome P450 monooxygenases (CYP) and 
epoxide hydrolase (EH)). However, studies have failed to identify any association 
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between DHS and polymorphism in genes encoding these drug metabolizing 
enzymes.
9,15,28
 Subsequently, attention was focused towards genes involved in immune 
response, such as the HLA gene, which encodes the major histocompatibility complex 
(MHC), a major player in the antigen presentation process.
29
 A number of HLA alleles 
were found to be associated with hypersensitivity reactions to different drugs; however, 
the strongest association was found between the HLA-B*1502 allele and the 
development of CBZ-SJS/TEN in Southeast Asian populations, with an odds ratio of 
2504.
13
 This allele was also found in high frequency in these populations, which may 
explain the higher prevalence of SJS/TEN cases due to CBZ use among Southeast 
Asians.
17
 This finding suggests a functional role of the HLA-B*1502 allele in CBZ-
SJS/TEN pathogenesis, a hypothesis that is not yet proven.
27
 
The cases presented here provide further biochemical and genetic insights into the 
distinct pathogenesis of non-bullous CBZ-DHS and CBZ-SJS/TEN. A clinically 
confirmed typical case of CBZ-induced SJS (according to the international standard 
criteria
30,31
) in an HLA-B*1502 allele positive patient of Han Chinese origin represented 
a useful opportunity to investigate the latter assumption. We have also tested a typical 
non-bullous CBZ-DHS Caucasian patient. Our biochemical approach using two in vitro 
testing systems revealed unexpected results (Table 1). We believe that our data are 
consistent with distinct pathophysiological pathways within subsets of CBZ-DHS. 
Specifically, in this case the immunological pathway is active whereas the toxic 
metabolite pathway is not. 
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Several working hypotheses have been proposed to explain the pathophysiological 
mechanisms underlying DHS. The first to be introduced was the hapten hypothesis (HH), 
which assumed that a small drug molecule can be recognized by the immune system only 
after forming an adduct with endogenous peptide.
32
 The reactive metabolite hypothesis 
attributes DHS to imbalance in bioactivation and detoxication of the drug resulting in 
larger quantities of toxic metabolites in the body.
10
 The danger hypothesis considers 
signals released by stressed and dying cells (e.g., cytokines, HSP, NO, ROS) as a 
requirement to fully activate an immune response.
33
 Finally, the pharmacological 
interaction with immune receptor hypothesis (p-i Hypothesis) has proposed another scenario 
to activate the immune system by a small molecule. It postulates that drug molecules (parent 
drug or metabolites) can directly bind non-covalently to T-cell receptors (TCRs) and activate 
T-cells independent of gene processing and presentation.
34
  
Undoubtedly, activation of the drug to an active metabolite is a prerequisite to 
initiate a cascade of events leading to development of DHS. As depicted in Figure 1, 
activation of the parent drug to an electrophilic reactive metabolite is likely to represent 
the first step in a cascade of events leading to the ADR. Several lines of evidence 
strongly suggest that metabolic activation is the first step in DHS.
35
 Cells (peripheral 
blood monocytes, PBMCs and platelets) from drug hypersensitive patients are more 
susceptible to the in vitro toxicity of the toxic drug metabolites than are cells from 
healthy control individuals.
11,36,37
  
Enhanced in vivo concentrations of the toxic metabolites fit well with the suggested 
DHS mechanism. First, high level of cytotoxic reactive metabolites in either the 
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metabolizing cells (e.g., hepatocytes or skin cells) or other tissues can cause cell necrosis 
and death providing „danger signals‟ to prime antigen presenting cells (APCs) and T-cells 
to be activated. These signals can be in the form of cytokines, HSP, NO or ROS released 
from necrotic or apoptotic cells. Second, these „dying‟ cells can also release haptenated 
proteins and peptides which can be processed by the APCs and presented as antigens. 
Finally, the metabolites can interact directly with the T-cells receptors (TCRs) and form a 
bridge with the MHC (class I and II) on APCs causing T-cell activation and expansion of 
T-cell clones (the p-i hypothesis).
34
 It must be pointed out that these various hypotheses 
are not mutually exclusive. Thus, the formation of ROS can result in the production of 2-
hydroxynonenal, an endogenous electrophile that could mimic a drug in terms of covalent 
reaction with proteins, and enhance the immunological response and the severity of an 
ADR.
38
 
According to the classical theory of antigen presentation, activated APCs carrying the 
antigen will migrate to a local lymph node and present the antigen in the context of the 
MHC (classes I and II) to naive or memory T-cells which will then expand and initiate 
the immune response.
39
 Antigens formed in the cytosol of APCs are presented on MHC I 
to CD8+ cytotoxic T-cells; whereas, extracellular antigens are presented on MHC II to 
CD4+ helper T-cells. Each of these types of immune response has its own characteristic 
pathway and cytokine profile and can result in distinct clinical manifestations.
23,39,40
 
Accordingly, the subsequent events along the pathway are determined by the expansion 
of specific T-cell clones that will propagate the immune response and determine the 
clinical signature of the reaction.
41
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CD8+ T-cells are known to produce cytokines such as IFN-γ and TNF-α, which 
increase the surface expression of MHC, and their cytotoxic effects are thought to be 
mediated by Fas death receptor through increasing the expression of its legend FasL or by 
a perforin/granzyme B dependent pathway.
42
 These mediators are highly expressed in 
skin from SJS/TEN patients.
43
 On the other hand, CD4+ T-cells produce IL-4 and IL-5 
leading to eosinophil recruitment and features characteristic of non-bullous DHS. 
However, it is noteworthy that most of the details of DHS signalling pathways are 
unknown at the present time, in part because of the lack of validated animal models for 
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Figure 1: The reactive metabolite, hapten, danger and p-i hypotheses and their suggested 
involvement in DHS. When a lipophilic drug molecule enters a biological system it will, 
in most cases, be readily metabolized to either chemically reactive or non-reactive 
metabolites. The reactive metabolites are in turn converted to less toxic or non-toxic 
products. An imbalance in these processes can result in the enhanced concentration of 
reactive toxic metabolites in vivo that can cause either necrotic or apoptotic cell death, 
releasing the „danger signals‟ and haptenated self-peptides that can be processed by 
specialized antigen presenting cells (APCs) and presented to specific T-cell clones. These 
T-cell clones expand upon activation and mediate the immune response (see text for more 
details). Certain alleles that were found to associate with a high risk of CBZ-DHS are 
presented in boxes along the pathway. CBZ: carbamazepine, APCs: antigen presenting 
cells, MHC, major histocompatibility complex. 
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these types of reactions.
44
 It is unlikely that CBZ works only as a classic hapten-forming 
drug (e.g., penicillin‟s) because penicillin‟s can induce all types of hypersensitivity 
reactions in the „Coombs and Gell‟ classification (types I-IV)45 whereas CBZ induces 
only type IV reactions.
46,47
 Furthermore, no endogenous immunologically-relevant 
protein target has been identified to be haptenated by CBZ metabolites.  
The recent finding of genetic predisposition to CBZ-SJS/TEN (but not non-bullous 
CBZ-DHS) in individuals from Southeast Asian suggests a difference in the 
pathophysiology of these two variations of ADRs caused by CBZ. This concept is 
supported by our current study in which a Han-Chinese descendent with CBZ-SJS and 
positive HLA-B*1502 allele was negative to both LTA and iPTA in vitro toxicity assays. 
We earlier reported that LTA has a sensitivity of 85-100% in well documented CBZ-
DHS cases.
48
 Such a finding strongly suggests that the severe bullous reactions caused by 
CBZ (CBZ-SJS/TEN) may have distinct pathophysiology from non-bullous CBZ-DHS, 
which is not detected by these in vitro toxicity assays. 
It is apparent that hypersensitivity reactions (bullous and non-bullous) have different 
pathophysiological mechanisms. Individuals prone to form enhanced concentrations of 
toxic metabolites of drugs that cause ADRs may also carry genes that predispose to 
immunotoxicity from metabolite-protein or by-product-protein adducts. While these 
variables might co-exist in individuals with a high frequency of HLA-B*1502 allele, such 
as is the case for Southeast Asians, development of CBZ-SJS/TEN in patients who carry 
the HLA-B*1502 allele does not seem to depend on reaching a threshold of reactive 
metabolites.  
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Another feature that differentiates non-bullous reactions from SJS/TEN is the 
involvement of viral reactivation, particularly human herpes virus 6 (HHV-6) which has 
been observed in most non-bullous DHS cases but is not observed in SJS/TEN cases.
7,49
 
This has led some investigators to establish HHV-6 reactivation as one of the diagnostic 
criteria of DHS.
50
  
Overall, these observations suggest that the process of activating APCs and antigen 
presentation may not be a major contributor in CBZ-SJS/TEN development but, rather, 
that interaction among the parent drug (or metabolite(s)), TCR and MHC (Probably class 
I, HLA-B*1502) are the main components that initiate the immune response that 
manifests in CBZ-SJS/TEN. In line with the p-i hypothesis this scenario is quite possible 
and may explain why certain HLA alleles are associated with specific immune 
responses.
51
 Such an effect would be independent of drug bioactivation and hapten 
formation and processing, which could explain why the in vitro toxicity assays were 
negative in the Han-Chinese child case we presented here. 
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7.1. Introduction 
Drug hypersensitivity reactions (DHRs) are uncommon but potentially fatal adverse 
events. Their diagnosis and prediction is difficult due to variable presentation and 
overlap of symptoms with other clinical conditions. Systemic rechallenge is 
considered as a gold standard for the diagnosis of DHRs; however, this may have 
severe consequences. In vitro tests are currently not sufficiently reliable to provide 
the basis for clinical decisions. This article summarises the challenges facing in vitro 
testing for DHRs.  
 Adverse drug reactions (ADRs) account for 6.5% of all hospital admissions and 
occur in 10-20% of hospitalized patients.(1, 2) Most ADRs (85-90%) are predictable, 
dose-dependent and related to the pharmacology of the drug (Augmented or Type A 
reactions), but 10-15% are unpredictable, unrelated to the known pharmacology of the 
drug and do not have a clear dose dependency (Bizarre or Type B reactions).(3) Drug 
hypersensitivity reactions (DHRs) or drug hypersensitivity syndrome (DHS) are a major 
sub-type of Type B reaction. The terms „Type B ADRs‟, „idiosyncratic drug reactions‟ 
and „drug hypersensitivity‟ have been used to describe the same disease. DHS is a rare 
but potentially fatal disorder that occurs in susceptible patients following exposure to 
specific drugs. Classes of drugs most associated with DHS include β-lactam antibiotics, 
sulfonamides, dapsone, minocycline, terbinafine, azathioprine, allopurinol, NSAIDs and 
aromatic antiepileptics. DHRs include all immune-mediated drug hypersensitivity 
reactions ( Types I to IV) while DHS refers more specifically to specific reactions 
characterized by delayed-onset constellation of symptoms including fever, rash and 
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multiple organ involvement. It has not been possible to accurately define the true 
incidence of DHRs due to difficulty in identification and classification as well as 
relatively few comprehensive studies, but it has been estimated to represent one sixth of 
all ADRs.(4)   
Our incomplete understanding of the etiology and pathophysiology of DHRs has 
made it difficult to come to agreement on their classification and nomenclature. However, 
a general classification of „allergic reactions‟ has been adopted to describe DHRs (Table 
1).(5) The Gell and Coombs classification for immune-mediated reactions does not 
provide a mechanistically comprehensive classification system for DHR but it is a 
clinically relevant system that classifies DHRs into immediate, accelerated and delayed 
reactions related to the temporal relationship between introduction of the causative agent 
and appearance of the symptoms (Table 1).
 
(6)  
  The clinical presentations and presumably the pathophysiology of DHRs are 
diverse and complex which make selection of an in vitro approach for their diagnosis or 
prediction a challenging task. Available in vitro tests are based either on detecting 
activation of the immune system (e.g., measuring immunoglobulins or immune cell 
activation) or detecting an enhanced ratio of metabolic activation to detoxication, an 
imbalance in drug metabolism (e.g., measuring cell susceptibility to in vitro chemical 
insult in metabolically-competent systems, Figure 1). The first category includes tests 
that measure drug specific IgE such as RAST (radioallergosorbent test), activation of 
basophils (BAT) or T-lymphocytes (e.g., the lymphocyte transformation test, LTT). The 
latter category includes the lymphocyte toxicity assay (LTA) as well as the recently 
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Table (1): Classification of immune-mediated hypersensitivity reactions (A) and classes 
of drugs most associated with causing delayed-type DHRs (B). 
 
 
 167 
 
AGEP, acute generalized exanthematous pustulosis; FcR, Fc receptor; DHRs, drug hypersensitivity 
reactions. Adopted from Pichler et al., 2010 (23); Coombs and Gell, 1975 (5); Levine and Ovary, 1961 (6) 
A):  Classification of immune-mediated hypersensitivity reactions 
Type mediator Pathogenesis Clinical picture Chronology 
I IgE Degranulation of Mast 
cells and basophils 
Urticaria; Anaphylaxis; 
Allergic rhinitis; 
Bronchospasm; 
Angiooedema; 
Immediate  
(≤ 1 hr) 
II IgG/M FcR dependent cell lysis Blood Cell Dyscasia Intermediate 
(5-14 days) 
III IgG/M FcR-dependent immune 
complexes deposition 
Serum Sickness; 
Vasculitis 
Arthus reaction 
Intermediate 
(7-8 days) 
IVa TH1 (IFNγ, 
TNFα) 
Monocyte/macrophage 
mediated inflammatory 
response 
Eczema Delayed 
(1-3 weeks) 
IVb TH2-IL4, IL5, 
IL13) 
Eosinophils mediated 
inflammatory response 
Maculopapular 
exanthema 
Bullous exanthema 
Delayed 
(2-7 weeks) 
IVc Cytotoxic T 
cells 
(Perforine, 
Granzym B, 
FasL) 
Cytotoxicity/Apoptosis Maculopapular 
exanthema 
Bullous/pustular 
exanthema 
Delayed 
(1-3 weeks) 
IVd T cells (IL8, 
CXCL8, GM-
CSF) 
Neutrophils mediated 
inflammatory response 
AGEP 
Behςet’s disease 
Intermediate 
(≤ 2 days) 
B): Drugs and classes of drugs most associated with delayed-type DHRs. 
 β-lactam antibiotics 
 Sulfonamides 
 Aromatic antiepileptics 
 Dapsone 
 Minocycline 
 
 Terbinafine 
 Azathoprine 
 Allopurinol 
 NSAIDs 
 Quinolones 
 Abacavir 
 Nevirapine 
 Iodinated contrast 
media 
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 described in vitro platelet toxicity assay (iPTA).(7) This article focuses on the current 
status of the in vitro diagnosis of immune-mediated DHRs by describing these tests their 
strengths and weaknesses, as well as possible future directions of this quickly evolving 
field. 
7.2. Challenges in the evaluation of DHS 
 Factors that contribute to the difficulty of diagnosis of DHS include variable 
clinical picture, overlap with other clinical conditions (e.g., infection or malignancy) and 
the typical delayed temporal relationship between administration of the causative drug 
and the appearance of symptoms.(8)   An active debate on whether this constellation of 
symptoms represent different degrees of severity of the same disease or distinct 
pathological entities is ongoing.(9, 10)   Systemic re-challenge is not ethically acceptable 
because of the possibility of severe adverse effects to the patient.  Currently, the 
diagnosis of DHS is based on the expertise of the treating physician and a comprehensive 
clinical work-up of individual cases. This includes detailed clinical and medical histories 
and thorough physical examination with laboratory data such as evaluation of liver 
function and blood counts as needed.  
 Developing an in vitro system for the evaluation of DHS would be of great 
advantage to researchers, drug regulators and clinicians.  To appreciate potential 
approaches, it is important to first consider briefly the putative pathogenesis of DHS.  
Briefly put, immediate onset reactions typically are mediated by an antibody such as IgE.  
Delayed onset DHS appears to evolve as a result of the complex interplay of a number of 
variables (Table 1). This appears to begin with bioactivation, given that a common 
 169 
 
characteristic of drugs causing DHS is the capacity to undergo metabolism to a reactive 
intermediate.  While there are two competing theories as to the evolution of DHS, the 
most widely held hypothesis is that reactive drug intermediates alter the cellular 
environment and react with cellular macromolecules, following which these altered 
macromolecules are processed by the immune system.  The immune response generated 
then determines the clinical expression of drug exposure – immune-tolerance or DHS.  
Thus, in vitro approaches to the evaluation of DHS would ideally evaluate key steps in 
the putative pathogenesis (Figure 1). 
7.3. In vitro approaches to drug hypersensitivity reactions. 
 In vitro testing has the advantage of being safe. Selection of an in vitro diagnostic 
test for DHS depends on the type of reactions and the underlying pathophysiology 
predicted from the clinical picture and the natural history of the reaction. There are in 
vitro tests best used for immediate IgE-mediated reactions and those that are better for 
non-immediate or delayed reactions. 
7.3.1. In vitro tests for immediate drug hypersensitivity reactions (DHRs). 
 In vitro tests for immediate hypersensitivity are based primarily on determination 
of specific IgE antibodies believed to be key mediators of Type I reactions. RAST, 
cellular fluorescent assay-IgE (CAP-IgE) and enzyme-linked immunosorbent assay 
(ELISA) are commonly used technologies which are known to have high positive 
predictive value (PPV) and low negative predictive value (NPV).(11) Thus, positive 
results strongly indicate immune mediation of the reaction but negative results do not 
exclude this possibility.  Thus, either skin tests or rechallenge is required to determine 
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Figure (1): Pathogenesis and in vitro tests used for the diagnosis and prediction of 
immune-mediated DHRs (see text for details). A, activation; APC, antigen presenting 
cells; BAT, Basophil Activation Test; D, detoxication; iPTA, in vitro Platelet Toxicity 
Assay; LTA, Lymphocyte Toxicity Assay; LTT, Lymphocyte Transformation Test; 
TCR, T cell receptor. 
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safety of future therapy.  As an example, one commercially available test (CAP-FEIA, 
Phadia
®
) was found to have sensitivity between 0 and 25% and specificity ranging from 
83.3% to 100%, respectively, in diagnosis of immediate reactions to β-lactam antibiotics 
and the variation was reported to be dependent on the clinical manifestations.(12) 
Measurement of drug specific IgE antibodies is widely used for diagnosis of immediate 
reactions to β-lactam antibiotics, muscle relaxants and some NSAIDs.  
 Another cellular in vitro test for immediate hypersensitivity is the basophil 
activation test (BAT). Basophils respond to antigen stimulation in vitro by degranulation 
(e.g., release of histamine and leukotrienes) and expression of certain surface markers 
(e.g., CD45, CD11b, CD11c, CD62L, CD203c and CD63). Release of mediators 
including histamine can be measured in the media as an indicator of basophil activation 
although this method is limited by low sensitivity. Sensitivity was increased by the use of 
fluorescent antibodies for these surface markers coupled to flow cytometry. This latter 
test has been useful as an allergenic diagnostic approach and has been  validated 
clinically for Type I reactions to muscle relaxants(13), β-lactam antibiotics(14), 
pyrazolones and certain NSAIDs(15, 16). The disadvantages of BAT include its 
relatively low sensitivity and its availability for only a limited number of drugs (Table 
2).(17) 
 The lymphocyte transformation test (LTT) is a cellular test based on measurement 
of drug-specific T cells in samples of peripheral blood from patients with a suspected 
DHR. Although this test is mainly used for assessment of delayed T cell-mediated 
reactions (see below) positive LTT results also occur with type I (IgE-mediated) 
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reactions.(18) Although this may appear contradictory, it must be recalled that the 
production of drug-specific antibodies requires activation of T cells. 
7.3.2. In vitro tests for non-immediate (delayed) hypersensitivity reactions 
 Delayed, presumably T-cell-mediated, DHRs are believed to be a result of a 
complex interplay of many different factors and pathways. Biochemical and genetic 
approaches have recently begun to shed some light on the pathophysiology of these types 
of devastating and potentially lethal ADRs. Understanding this pathophysiology is a 
prerequisite for development of evidence-based and biologically grounded approaches to 
manage this disease. Although some exceptions do exist, metabolic activation of drugs to 
metabolites normally represent the first step in the cascade of events leading to 
development of DHR(19) The „reactive metabolite hypothesis‟ posits that DHR develops 
as a result of imbalance between metabolic activation or toxication and detoxication of 
drugs in the biological system leading to accumulation of one or more toxic reactive 
metabolites.(20, 21) DHS is always associated with either drugs known to be 
electrophilic or those readily bioactivated to electrophilic metabolites capable of 
covalently modifying endogenous macromolecules, including proteins and DNA.(22) It is 
important to understand that „reactive metabolites‟ may not be the principle direct 
activator of the immune system as parent, non-reactive drugs can activate isolated T-cells 
in vitro without need for any bioactivation.(23) However, chemically reactive 
electrophilic metabolites seem to be the major, if perhaps not the only, products capable 
of  supporting two important pathways in the immune system activation process: 
generation of haptenated endogenous proteins (act as antigens, signal 1) and generation 
of danger signals from stressed and dying cells (signal 2, Figure 1).(9) Signal 2 can also 
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be provided by factors such as trauma, bacterial and viral infections, or co-administered 
drugs and environmental pollutants. The clinical manifestations of DHS are probably 
primarily mediated by the immune system although in some cases a direct toxic effect of 
the reactive species generated from the drug during metabolism may be manifested 
clinically.(24) As an example, the immune response may be responsible for the skin 
reaction whereas enhanced formation of cytotoxic metabolites may result in liver or 
kidney dysfunction.  It has been established for several decades that cells from DHS 
patients (peripheral blood mononuclear cells, PBMCs) are more susceptible to in vitro 
toxicity from the reactive metabolite(s) of the suspected drug than are cells from healthy 
individuals (controls) who have tolerated the drug.(25)  These observations prompted the 
development of the lymphocyte toxicity assay (LTA).(26)  
7.3.3. The lymphocyte toxicity assay (LTA) 
 The LTA is performed by isolation of PBMCs (lymphocytes) from blood samples 
withdrawn from patients and incubation of these cells with the suspected drug metabolite 
(if known and available) or the parent drug in the presence of a metabolic activation 
system (usually Phenobarbital-induced rat liver microsomes, RLM).(27) Following 
incubation with different concentrations of the tested drug for 2 h at 37°C, cells are 
allowed to recover for 16 hr and viability is then determined using different methods 
(e.g., trypan blue exclusion, MTT). Degrees of cell death are then expressed as 
percentage of the control and compared with percentage of cell death in cells from 
healthy individuals who do not experience an ADR with the same drug (controls).  A pre-
selected increase in the percentage of cell death of incubated patient cells (vs controls) is 
considered as an indication of patient susceptibility.(28) The predictive value of this test 
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remains difficult to define due to lack of a „gold standard‟ test for comparison, and the 
technical complexity of the test.  
 We have recently performed a population survey on a cohort of pre-tested patients 
to evaluate the predictive values of the LTA for diagnosis of DHS.(29) In this study we 
included 147 patients who developed a DHS to primarily 3 different classes of drugs, β-
lactam antibiotics, sulphonamides or aromatic anticonvulsants. It is clear from our 
evaluation that the performance of the LTA test is different in cases involving each one 
of these drug classes.(29)  
 The most complicated and non-standardized step in the test is the metabolic 
activation system using RLM. In some cases  a murine system will not generate the same 
metabolite(s) of a particular drug at the same concentration(s) as would be generated in 
humans in vivo over the course of therapy. There are many pharmacokinetic and 
pharmacodynamic factors in humans that are unaccounted for in the in vitro activation 
systems, including lack of several functional detoxication pathways. This is supported by 
the observation that use of the synthetic reactive metabolite (as in case of sulfonamide 
drugs) resulted in increased test sensitivity and a positive predictive value of 100% (29).  
Another factor limiting the more routine use of the LTA is the requirement for careful 
isolation of white blood cells. Therefore, we have explored the possibility of using blood 
platelets as an alternate cell model for in vitro toxicity testing.(27) 
7.3.4. The in vitro platelet toxicity assay (iPTA) 
 In order to overcome many of the limitations of the LTA test and to simplify the 
procedure to encourage wider clinical use, recent research in our lab focused on 
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development and validation of peripheral blood platelets (thrombocytes) as a surrogate 
cell model for in vitro toxicity testing.(7) Thrombocytes are metabolically active non-
nucleated cells of  2.0 to 5.0 µm in diameter, 0.5 µm in thickness and abundance of 150-
450×10
9
 cells/L.(30) Due to their small size and low density, they are readily collected 
from peripheral blood using differential centrifugation.(31) In addition to blood 
homeostasis, their role in inflammation, allergy and hypersensitivity reactions has 
recently been recognized.(32-35) Thrombocytes have active mitochondria and complete 
apoptotic system, suggesting they can serve as a cellular model for studying drug 
toxicity. Furthermore, they do not proliferate which is an advantage in studying the 
degree of cell death. We have found that platelets from hypersensitive patients respond to 
in vitro chemical insult in a similar fashion to PBMCs; however, the degree of cell death 
is greater and easier to detect.(7) We speculate that platelets have lower capacity for 
detoxication of reactive metabolites. 
 Validation of any novel diagnostic test requires the availability of a „gold 
standard‟ for comparison. Unfortunately, this is lacking in DHS because systemic 
rechallege data are generally unavailable. To validate the novel iPTA we used two 
approaches: (i) inclusion of rigorously identified DHS cases known to be caused by 
treatment with sulphonamide drugs (sulfa-DHS);  and (ii) the use of the LTA, which we 
showed to have a positive predictive value of 100% in cases of DHS due to sulfa drugs in 
patients that had been clinically re-exposed.(29) Using a 20% increase in cell death as a 
cut-off value, there was 85% agreement (11 out of 13) between the LTA and the iPTA 
results in the 13 sulfa-DHS cases we tested.(36) In the two cases where the two tests did 
not agree the LTA was negative and the iPTA was positive, and of importance, these two 
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cases were clinically confirmed as sulfa-DHS cases. We think that this disagreement 
between the LTA and the iPTA results from the higher sensitivity of the platelet test to 
detect patient susceptibility.  
 The iPTA offers a simplified procedure for in vitro toxicity testing for DHS with 
higher sensitivity than the LTA. We believe that the iPTA is more suitable as a diagnostic 
procedure for DHS for wider clinical use than the LTA. 
7.3.5. The lymphocyte transformation test (LTT) 
 A frequent feature of DHS is the presence of drug specific T-cell clones in the 
circulation of affected patients. These drug specific T-cell clones can be isolated and 
cloned in vitro; typically, they respond to incubation with the culprit drug with 
proliferation and expression of certain surface markers.  Cell proliferation and surface 
markers can be measured using different methods and have been used as a measure of 
specific immune system response to the drug. This technique also involves isolation of 
PBMCs using differential gradient centrifugation and is prone to the same technical 
complexity as the LTA, a limitation that confines its use to well equipped research labs  
rather than labs designed for clinical diagnosis.(37) For a detailed description of this test 
procedure and its history please refer to Elzagallaai et al., 2009.(27) 
  
The LTT has been useful in defining clonal responses to drugs implicated in DHS. 
While these clones have been helpful in studying the immune response to drugs and drug 
metabolites, the LTT suffers from the same difficulty in extrapolating in vitro responses 
to in vivo clinical conditions as does the LTA.   
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Table (2): Advantages and disadvantages of in vitro tests used for diagnosis and 
prediction of DHRs. 
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The sensitivity of the LTT for the diagnosis of DHS has been estimated to be from 56% 
to 78% and its specificity to range from 85% to 93%.(27) There are many factors that 
were found to affect the predictive ability of the LTT which include: (i) timing of the test 
in respect to the initial reaction; (ii) the clinical picture of the reactions; (iii) the type of 
drug involved; and (iv) the test procedure and read-out systems used. 
7.4. Conclusion and future directions 
 Evaluation and management of immune-mediated DHRs require a great deal of 
clinical and laboratory experience and expertise.(38, 39) Advantages and disadvantages 
of the currently used in vitro tests for DHRs are summarized in table (2). We believe that 
the major current challenge for better in vitro approaches is incomplete understanding of 
the underlying pathophysiology of these complex ADRs. Genetic testing for predisposing 
alleles for DHRs has recently increased exponentially as the methodology to study the 
genome becomes more sophisticated while simultaneously per-test cost has declined. 
Genetic analysis has linked a few specific ADRs with certain polymorphisms for certain 
drugs in specific ethnic groups (e.g., HLA B*-1502 for carbamazepine-induced severe 
bullous reactions in the Han Chinese and HLA B*-5701 and abacavir 
hypersensitivity)(40). However, these studies have also made it clear that much more 
work is required in both basic and clinical science to enable us to better predict, manage 
and prevent this type of ADRs.  Further research is required to elucidate the 
pathophysiology of DHS as well as rigorous trials to determine which of the available in 
vitro evaluations is most suitable for the assessment of patients or research subjects with 
possible DHRs.   
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